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Abstract
This PhD thesis presents the work carried out at Center for Biological Se-
quence Analysis, Technical University of Denmark. The projects presented
in this thesis are a purely bioinformatic in nature. Included in this thesis are
the two projects that focus on the gene regulatory events mediated by miR-
NAs in the context of cancer biology, drug resistance and disease progression.
The ﬁrst project described in Chapter 6 addresses the problem of tamox-
ifen resistance, an anti-estrogen drug that is generally highly eﬀective in
the treatment of ER-positive breast cancers. The underlying molecular
mechanisms for the acquired resistance to tamoxifen are not very well un-
derstood. Therefore, with the aid of miRNA and gene expression proﬁles for
MCF7/S0.5 (tamoxifen sensitive) and three MCF7/S0.5 derived tamoxifen
resistant cell lines, we obtained several miRNA-mediated regulatory events
in the tamoxifen resistant cell lines. Following a systems biology approach of
integrating evidences of functional interactions such as transcription factor
(TF)-miRNA interactions, we have identiﬁed a number of biologically rele-
vant pathways involved in the development of tamoxifen resistance.
Chapter 7 presents a study highlighting the role of miRNAs in the trans-
formation of ocular mucosa associated lymphoid tissue lymphoma (MALT)
to the high-grade diﬀuse large B-cell lymphoma (DLBCL) of eye. Several
tumor suppressive miRNAs were found to be dysregulated in DLBCL, sug-
gesting their possible role in disease transformation. Many of those were
under transcriptional regulation by MYC and NFKB1, the key transcription
factors involved in lymphomas. Furthermore, upstream regulators of NFKB1
were also repressed, suggesting a possible loss of regulation of NFKB1 may
contribute to the activation of NF-B signaling pathway, and thereby to the
disease transformation.
In summary, this thesis focuses on regulatory role of miRNAs in drug re-
sistance and disease progression. The ﬁndings provide hints toward various
biologically and perhaps therapeutically relevant gene regulatory events.
This thesis demonstrates the right choice of data analysis techniques com-
bined with a systems biology approach provides better understanding of the
complex biology.
DANSK RESUMÉ vii
Dansk resumé
Denne ph.d.-afhandling præsenterer arbejde, der er udført på Center for
Biologisk Sekvensanalyse, Danmarks Tekniske Universitet. De projekter, der
præsenteres i denne afhandling er rent bioinformatiske af natur. Inkluderet
i denne afhandling er to projekter, der fokuserer på de gen-regulerende
begivenheder medieret af miRNA i forbindelse med cancer biologi, lægemid-
delresistens og sygdomsprogression.
Det første projekt beskrevet i kapitel 6 addresserer problemet vedrørende
tamoxifen resistens, et anti-østrogen stof, som generelt er yderst eﬀektiv i
behandlingen af ER-positive brystcancere. De underliggende molekylære me-
kanismer i erhvervet resistens over for tamoxifen, er ikke særlig godt forstået.
Derfor, ved hjælp af miRNA- og genekspressionsproﬁler for MCF7/S0.5
(tamoxifen følsom) og tre MCF7/S0.5 aﬂedte tamoxifen resistente celleli-
nier, kom vi over adskillige miRNA-medierede regulatoriske begivenheder
i tamoxifen resistente cellelinier. Efter en systembiologisk tilgang til at
integrere beviser for funktionelle interaktioner såsom transskription faktor
(TF)-miRNA interaktioner, har vi identiﬁceret en række biologisk relevante
veje, der er involveret i udviklingen af tamoxifen resistens.
kapitel 7 præsenterer en undersøgelse der fremhæver miRNAers rolle i om-
dannelsen af okulære slimhinde associeret lymfevæv lymfom (MALT) til den
højt rangeret diﬀuse storcellet B-celle lymfom (DLBCL) i øjet. Flere tumor
undertrykkende miRNA viste sig at være fejlreguleret i DLBCL, hvilket ty-
der på deres mulige rolle i sygdom transformation. Mange af dem var under
transkriptionel regulering af MYC og NFKB1, de vigtigste transkriptions-
faktorer involveret i lymfomer. Desuden var opstrøms regulatorer af NFKB1
også undertrykt, hvilket tyder på et muligt tab af reguleringen af NFKB1
kan bidrage til aktivering af NF-B signalvejen, og dermed aktiveringen af
sygdomstransformation.
Sammenfattet fokuserer denne afhandling på den regulatoriske rolle af
miRNA i lægemiddelresistens og sygdomsprogression. Resultaterne giver
antydninger af forskellige biologiske og måske terapeutiske relevante gen-
regulatoriske begivenheder. Denne afhandling viser det rigtige valg af da-
taanalyseteknikker kombineret med en systembiologi tilgang giver bedre
forståelse af den komplekse biologi.
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Part I
Introduction
1

Chapter 1
MicroRNAs
MicroRNAs (miRNAs) are 19-22 nucleotide long small noncoding RNAs
that regulate expression of several genes via post-transcription repression
or degradation in both animals and plants. Due to their huge regulatory
potential, miRNAs have garnered a great amount of research interest. This
chapter outlines the current understanding of miRNA biogenesis and moves
further to highlight the mechanisms of miRNA-mediated gene regulation,
target prediction algorithms and roles of miRNAs in cancer.
1.1 miRNA biogenesis
After the discovery of lin 4 and let 7 in Caenorhabditis elegans [108, 148],
miRNAs were reported in mammals [103, 107], plants and viruses. miRNAs
stem from more than 1kb long primary (pri-) miRNAs. The pri-miRNAs
are synthesized by RNA polymerase II (Pol II). In mammals, a complex
involving Drosha and Pasha proteins form a microprocessor complex with
pri-miRNAs. This cleavage of pri-miRNA results in the double stranded
miRNA precursors (pre-miRNAs). Pre-miRNAs are hairpin loops of about
150 nt lengths. As shown in Figure 1.1, the pre-miRNAs are exported from
nucleus to the cytoplasm by the Exportin, where Dicer, an RNAase enzyme
and its binding partner TRBP/Loqs separate two strands and form an
unstable miRNA:miRNA duplex of 22 nt length. One of the strands from
this duplex, called the guide strand, is selected by Argonaute and loaded
into the RNA-induced Silencing Complex (RISC) where miRNA binds with
its mRNA targets [103, 72, 96, 106]. The opposite strand, now a passenger
strand, is normally degraded, but recent studies using deep sequencing tech-
nologies have made it clear that the miRNA strand often remains viable
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and coexists with the mature miRNA from the opposite arm.
Figure 1.1. MicroRNA biogenesis [92]
MicroRNAs typically transcribe from a variety of genomic regions such
as, intergenic regions, introns of protein coding genes or intron/exons of pro-
tein and/or noncoding genes. At least 50% of human miRNAs are intronic,
meaning that precursor miRNAs are transcribed from the introns of protein
coding or nonprotein-coding genes [154], whereas about 10% are encoded
from the exons of protein-coding or nonprotein-coding transcripts. This sug-
gests that the expression of miRNA is often related to the expression of the
host transcripts from which they transcribe. Many intronic miRNAs lack
their own promoter, and utilize the promoter of the gene they reside in.
Therefore, the posttranscriptional regulation of the host genes often aﬀects
miRNA expression. Chien et al [31] recently published miRStart database
presenting a compiled information on miRNA and transcription start sites
(TSS) based on experimental evidences, covering 442 intronic miRNA-host
pairs in human genome. Using the miRNA and mRNA expression data de-
scribed in Chapter 6, Paper I, I found that 37 of the 156 miRNA-host gene
pairs considered showed high correlation of their expression levels measured
across breast cancer cell lines. In Table 1.1, the negative value of Pearson’s
correlation coeﬃcient (PCC) represent an agreement of miRNA expression
(measured by qPCR method) and mRNA expression (microarray) for each
miRNA-host pair considered. miRNA-host pairs showing positive correlation
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(PCC<0, due to qPCR vs RMA values) might be co-transcribed. It is also
commonly believed that the hosted intronic miRNAs exert functions that
complement the functions of the host genes they are transcribed from.
Table 1.1. Intronic miRNA-host gene pairs with high degree of
correlation of expression
miRNA Host gene PCC miRNA Host gene PCC
miR-107 PANK1 -0.68 miR-30e NFYC -0.63
miR-10b HOXD3 -0.9 miR-335 MEST -0.96
miR-1182 FAM89A -1 miR-378 PPARGC1B -0.6
miR-1201 CCNB1IP1 -0.89 miR-500 CLCN5 -0.97
miR-1243 ANK2 -0.99 miR-504 FGF13 -0.96
miR-1249 C22orf9 -0.9 miR-564 TMEM42 -0.82
miR-1258 ZNF385B -1 miR-586 SUPT3H -0.96
miR-1266 MYO5C -0.87 miR-589 FBXL18 -0.93
miR-1296 JMJD1C -0.77 miR-600 STRBP -0.85
miR-147b SPATA5L1 -0.72 miR-604 SVIL -0.91
miR-149 GPC1 -0.89 miR-620 MED13L -0.91
miR-152 COPZ2 -0.97 miR-639 TECR -0.67
miR-15b IFT80 -0.73 miR-640 GATAD2A -0.88
miR-1908 FADS1 -0.84 miR-643 ZNF766 -0.96
miR-1912 HTR2C -0.6 miR-744 MAP2K4 -0.91
miR-1914 UCKL1 -0.77 miR-941 DNAJC5 -0.8
miR-22 C17orf91 -0.88 miR-95 ABLIM2 -0.81
miR-23b C9orf3 -0.64 miR-98 HUWE1 -0.85
miR-27b C9orf3 -0.73
miRBase, an online repository of miRNA sequences and their annota-
tion, is a widely accepted source of miRNA information. The database was
established in 2002 to provide a consistent nomenclature for novel miRNAs
along with primary evidence supporting their annotations. Guidelines for
the miRNA nomenclature were deﬁned in 2003 [3]. In order for a 22 nt
sequence to receive a miRNA status, it must fold into a stable hairpin struc-
ture characterized by low minimum free energy (MFE). Furthermore, the
putative miRNA must have derived from, either an experimental cloning,
homology to the known miRNAs (with or without experimental veriﬁcation)
or miRNAs captured by sequencing technologies. Until the latest release
(miRBase 18), mature miRNA products arising from the “passenger” strand
of the hairpin were denoted as miR (miRNA star). Due to an increasing
number of evidences showing that miR sequences are functional, latest
release of miRBase (miRBase 18) has adopted -5p/-3p nomenclature. In
this thesis both miR and -3p/5p suﬃxes are used to denote mature miRNA
products.
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1.2 miRNA detection methods
Primary discovery of miRNAs has been through traditional, low-throughput
methods such as, northern blotting, cloning and PCR. Detection of miRNAs
is particularly diﬃcult and calls for a careful probe design due to their
unique set of characteristics. The short length of miRNAs (22nt) make it
diﬃcult to design primers. Further, the heterogeneity of the GC-content
of miRNA sequences oﬀer them a wide range of melting temperatures. In
addition, it is also diﬃcult to distinguish between the pri-miRNAs and the
precursors because of the mature miRNA sequence being present in both.
Lastly, high sequence similarities of miRNAs with its family members, often
to the extent of only single nucleotide, make it very hard to design detection
techniques that are speciﬁc and sensitive. Available options for miRNA
detection are northern blot, in situ hybridization, qPCR, microarrays and
sequencing technologies. Northern blotting and in situ hybirdization (ISH)
are low-throughput methdos, whereas qPCR, microarrays and NGS are the
high-throughput techniques. The latter are described in Chapter 4.
1.3 Silencing through miRNAs
Mature miRNAs bound to the RISC complex act as a template for recog-
nizing target genes. When the target gene is found, its down regulation is
achieved by three alternative mechanisms: mRNA cleavage, translational
repression and mRNA degradation. The choice of eﬀective mechanism de-
pends on the extent of complementarity between miRNA and its target site.
With the perfect or near perfect complementarity between miRNA and its
target, the site speciﬁc cleavage is carried out exclusively by Ago2 [74]. With
an imperfect complementarity, mRNA repression or degradation takes place
in the presence of four Ago proteins [180]. The mature miRNA forms a
complex involving, mostly, 3’ UTR region of its target and RNA-induced
silencing complex (RISC). Such an association of RISC to the target mRNA
results in a post-translational repression or RNA degradation.
miRNAs have been known to bind to the 3’ UTR of mRNAs to direct
their posttranscriptional repression. The seed region, starting from 2-8 nt
in the mature miRNA, provides the speciﬁcity of target recognition. There
always exists a complementarity between miRNA and its target site in the
seed region. However, target recognition based only on the seed match is not
suﬃcient for repression [71]. Length of the target site to which a miRNA
binds, and the degree of complementarity between the two is also important
to determine the extent of regulation. For example, repression of transcripts
with 8 nt (8-mer) target site has been seen more eﬀective compared to 7-mer
sites. In addition to the degree of complementarity and length of the target
site, various other features in the genomic context determine the eﬃcacy
of miRNA targeting. MiRNAs have also been shown to exhibit cooperative
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regulation at their shared target site. Having multiple target sites increases
the likelihood of target repression. Furthermore, the proximity of target sites
on the 3’ UTR, proximity of target sites of multiple miRNAs and the degree
of cooperativity of miRNAs are important factors inﬂuencing the eﬃcacy of
miRNA binding. Strength and eﬀectiveness of the binding is also determined
by G:U (wobble) pairing at the 3’ end of the seed region along with the
imperfect complementarity between miRNA:mRNA complex [135]. Further,
the evolutionary site conservation, and AU content around the target site
also determine miRNA target speciﬁcity and the eﬃcacy. Although there is
an evidence for miRNA targeting the 5’ UTR or the open reading frames
(ORF), gene regulation by the binding of miRNA with 3’ UTR is more
common. Also the length of 3’ UTR, as well as proximity of target sites to
the ends of UTR, have positive impact on the eﬃcacy of miRNA targeting,
perhaps due to the increased accessibility of the translation machinery at
the UTR ends.
1.4 MicroRNA target prediction
MicroRNA are expected to modulate the expression of hundreds of genes.
Since the transcriptional repression of miRNA targets and dysregulation of
miRNAs themselves have been linked to cancer and various other disorders,
it is of particular interest to accuarately identify targets of miRNAs. Ex-
perimental approaches of target identiﬁcation are expensive and resource
intensive [200, 167, 64]. Therefore, accurate computational tools for miRNA
target prediction are necessary.
Current challenges in the computational target prediction arise from
the imperfect complementarity between miRNA and target within the seed
region and the wobble (G:U) pair. Initial approaches for target prediction
relied on a near-perfect complementarity between mRNA and miRNA in
the seed region, i.e., position 2-8 in 5’ end of mature miRNA. To reduce the
number of false positives in the predictions, these algorithms used evolution-
ary sequence conservation across multiple species. Early algorithms based
on seed pairing and evolutionary conservation includes, TargetScan [61],
miRanda [11] and PicTar [104]. Later on, miRNA targeting events with an
imperfect target-site complementarity and non-conserved target-site were
reported and characterized. This lead to implementation of new algorithms
that allowed for moderately stringent seed pairing and included other deter-
minants of miRNA target recognition.
The extent of seed complementarity allowed by most of the target pre-
diction tools ranges from perfect match (TargetScan), single mismatch in
the seed region (PicTar) and multiple mismatches in the seed (miRanda
miRBase [69], PITA [95]; miRWIP [76]). A weak base-pairing to the 3’ end
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of miRNA could compensate for an imperfect binding of 5’ end of miRNA-
target complex; and the target sites often reside in non-conserved regions
(miRWIP [76], RNA22 [135], PITA). Recently, more careful approches to
target prediction have been developed that integrate the evaluation and
modeling of various sequence features surrounding the target sites, for ex-
ample, miRWalk [43] and miRSVR [10]. Experimentally validated sets of
miRNA targets are limited, but can be retrieved from MirWalk [43] or
miRecords [192].
Unfortunately, the degree of overlap between the predicted targets from
various algorithms is very low. False positive rates for some of the tar-
get prediction tools are estimated to be about 30% [25]. Further, many
algorithms often have inherent biases in predictions that come from their
target prediction criteria. Therefore, relying on the predictions from a single
tool may result in an increased number of true negatives. For both studies
described herein, I collected predictions from multiple tools (5 to 7) and
accept a gene as a predicted target only if it is predicted by more than one
prediction tools.
Some of the recent approaches integrate data from miRNA, gene and also
protein expression for a reliable prediction of miRNA targets. The method
of inferring the functional or eﬀective miRNA-target relationships assume
that the changes of miRNA expression could be reﬂected by the expression
changes of their targets [30, 5]. Inverse-correlations between miRNA and
predicted target gene expression are often used to ﬁlter out non-functional
miRNA-target pairs. In Chapter 6, Paper I, a similar approach has been
followed in inferring functional miRNA-target relationships.
1.5 miRNAs and cancer
miRNAs are often located within the fragile sites or at the regions that
are frequently ampliﬁed or deleted in human cancers [21]. For example,
miR-15 and miR-16 are located at 13q14, a frequently deleted region in
chronic lymphocytic leukemia (CLL) [21]; translocation of miR-17-92 clus-
ter containing region in T-cell acute lymphoblastic leukemia (T-ALL) and
lung cancer [128, 79, 141]; and an ampliﬁcation of miR-16a carrying region
in glioblastoma [85]. Further, transcriptional regulation of miRNAs by
transcription factors (TFs) has been observed in various cancers. Several
miRNAs are regulated by transcription factors such as MYC [47, 119, 140],
TP53 [35, 193] and RAS [93]. Craig et al. [38] suggested a role of MYC
repressed miRNAs in the transformation of low-grade gastric lymphoma
to high-grade diﬀuse large B-cell lymphoma (DLBCL). Taken together, an
aberrent expression of miRNAs is strongly associated with development and
disease transformation in cancers.
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Dysregulation of miRNAs is very likely to aﬀect expression of their target
genes. Depending on the function of miRNA targets, for example in the
cell growth, apoptosis and tissue diﬀerentiation, miRNAs assume oncogenic
(oncomiRs) or tumor suppressive roles. For example, tumor suppressor miR-
15/16 target BCL2 and induce apoptosis of cancer cells. These miRNA are
often down-reguated in CLLs [21]. On the other hand, let-7 family miRNAs
are tumor suppressor miRNA that modulate the expression of oncogenes
such as RAS [90, 109]. Also, depending on the tissue type and type of genes
they regulate, miRNAs may assume both, tumor suppressive and tumor
proliferative roles [163, 80].
miRNAs have recently found a great potential in diagnostics and thera-
peutics [91]. Anti-miR therapies to speciﬁcally target oncomiRs or such miR-
NAs oﬀering drug resistance are being developed [117, 121] and few of them
are already in the clinical trial phase (Santaris Pharma, ClinicalTrials.gov).
miRNA mimics, also known as “miRNA sponges” have been exploited to take
away oncogenic eﬀects of miRNAs (reviewed in Ebert et al.). Drug resistance
in various types of cancers have been attributed to aberrant expression of
miRNAs. For example, miR-221/222 expression is associated with resistance
to tamoxifen in ER-positive breast cancer [132]; miR-214 and miR-125b oﬀer
cisplatin resistance by targetting PTEN and Bcl-2, respectively [194, 98].
In summary, miRNA regulation due to chromosomal aberrations or by
upstream TF-regulators and miRNA-mediated regulation of speciﬁc genes
and pathways, contribute to the tumorigenesis, disease progression and
transformation. miRNAs also have a huge potential to be used in diagnos-
tics, prognostics and therapeutics.

Chapter 2
Breast cancer
Breast cancer is one the most frequent types of malignancies among women
from both, Western and Eastern worlds. In the past years, the incidence
of breast cancer has been increasing due to improved life expectancy and
lifestyle choices such as birth control pills, smoking, alcohol consumption
and urbanization. In this chapter, I will brieﬂy describe breast cancer,
classes of breast cancer, estrogen receptor (ER) positive breast cancer and
anti-estrogen treatment options for ER-positive breast cancer.
2.1 Breast cancer
Breast tissue is mainly made up of lobules, ducts and stroma. Each lobule
contains a network of milk producing glands, each terminating into the
papilla (nipple) via small ducts lined with myoepithelial cells [146]. The
milk ducts and lobules lie within adipocytes and connective tissue as shown
in Figure 2.1. Breast cancer is the malignancy that originates usually from
the ducts and lobules. However, the cancer cells can spread into the lymph
nodes, bloodstream and metastasize in other parts of the body.
Risk factors
Risk factors for breast cancer are numerous due to the complexity and het-
erogeneity of the disease. Mutations in BRCA1, BRCA2 and TP53 are the
most important risk factor, increasing the lifetime risk of developing breast
cancer at an early age [36].
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Figure 2.1. Anatomy of female breast: 1) chest wall (thorax), 2)
pectorial muscles, 3) lobules, 4) nipple, 5) areola, 6) lactiferous duct, 7)
fatty tissue, and 8) skin. Source: Wikipedia [124]
Other than genetic factors, lifestyle related risk factors are the following:
• Increasing age; the invasive types of breast cancers are more common
in women above an average age of 55 years [56].
• Alcohol consumption, smoking and lack of physical activity [174].
• Hormone therapy after menopause.
• Obesity in post-menopausal women, due to increased estrogen synthesis
from adipose tissue [156].
• Early age at menarche and late menopause.
• Oral contraceptives, as they increase the risk of breast cancer over a
long term use [24].
• Mutations in tumor suppressor or oncogenes caused by an exposure to
radiation or carcinogenic chemicals [174, 53].
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2.2 Classiﬁcation of breast cancer
Breast cancer, when put simply, is an uncontrolled growth of breast cells.
However, the heterogeneity and complexity of the disease is very well known.
Nevertheless, depending on the site of origin of cancer, breast cancers are
divided into two main types: ductal carcinomas and lobular carcinomas.
Ductal and lobular carcinomas come in invasive or noninvasive forms. The
invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) rep-
resent the majority of breast cancers. This type of carcinoma is inﬁltrative,
meaning that it may spread to other body parts via lymphatic system and
blood stream [159]. The noninvasive types of lobular and ductal carcinomas
place the patients at high risk of developing an aggressive form of the dis-
ease. Depending on the estrogen receptor (ER) status, these tumors can be
treated either by anti-estrogen alone or by primary treatment combined with
anti-estrogen drugs. Use of anti-estrogens in the second case is adjuvant to
the primary treatment, hence the term ”adjuvant therapy”.
Scope of anti-estrogens
As stated earlier, the heterogeneity in breast cancer tumors makes the dis-
ease complex; therefore, the diagnosis, prognosis and treatment options are
determined according to various criteria. Such distinctions are made based
on the tumor stage, grade (diﬀerentiation stage), immuniohistochemical
staining for receptor status as well as molecular markers obtained through
microarrays or other technologies.
The microarray technology (described in chapter 4) oﬀers a molecular
sub-classiﬁcation of breast cancer tumors according to their gene expression
proﬁles. Subtypes based on the molecuar characteristics are the following:
normal breast-like, basal, luminal, HER2/ERBB2 overexpressing, estrogen
and/or progesterone receptor-negative-HER2/ERBB2 negative (triple nega-
tive) breast cancers.
Luminal breast cancers, also covering most of the lobular carcinoma in situ
are more common (70% of the total cases) and are typically ER-positive [100].
Luminal A subtype, identiﬁed by high levels of ER expression, shows a
better survival [175, 176]. Whereas, luminal B subtype, characterized by low
expression of ER carries an aggressive and proliferative signature. About
50% of the HER2/ERBB2 over expressive tumors are ER-positive, but are
intrinsically resistant to tamoxifen or other anti-estrogen drugs [100]. We
will discuss anti-estrogen resistance in more details in section 2.3.2.
14 CHAPTER 2. BREAST CANCER
2.3 ER-positive cancer
ER is a ligand-activated transcription factor which is responsible for the
development and maintenance of female reproductive organs. Apart from
its primary functions, estrogen is also important for the development and
maintenance of musculoskeletal, cardiovascular and nervous system in both
males and females [40].
Estrogens are mainly synthesized from androgen in ovaries, but a small
amount of estrogen synthesis is also present in liver, adrenal glands and the
breasts. When ovaries are not functional, as in the case of post-menopausal
women, estrogens are produced through a conversion of androgens by aro-
matase enzyme present in the organs such as adipose tissue, breast tissue,
skin, brain, blood vessels and bones. Estrogens activate estrogen receptor
proteins, ER and ER by physical binding activities.
Activated ER binds to the estrogen responsive elements (ERE) located
upstream of the ER target genes. Alternative mechanism of activated
ER-binding involves various other response elements, such as AP-1 [102].
Experimentally validated transcriptional targets of the ER include MYC,
EGFR, JUN, CDKN1A, CCND1, CYP1, SPOE, FOS, TFF1, IL8 and
ITGA2, etc. as listed by TRED (Ttranscriptional Regulatory Element
Database) [198]. These genes are involved in the signaling events that
modulate cell diﬀerentiation, proliferation and apoptosis. In the presence of
acquired mutations in breast cells, an increased cellular proliferation results
into breast cancer. Induced levels of oncogenes are normally the culprit for
promoting proliferation of breast cancer cells.
2.3.1 Treatment of ER-positive breast cancer
Tumor size, stage and molecular characteristics, among others are the main
deterministic factors for treatment options. Surgical removal of a part
(lumpectomy) or entire breast tissue (mastectomy), and the surrounding
lymph nodes is common for cancers in advanced stage. To reduce the risk
of recurrence and eradicate any remaining cancer cells, patients are given
adjuvant therapy, such as radiotherapy combined with anti-estrogen drugs.
ER-positive breast cancers are treated with anti-estrogen drugs that work
by lowering the amount of estrogens in the body or by blocking estrogen
from attaching to the ER. Depending on their mode of action, anti-estrogen
therapy options can be classiﬁed as follows.
1. Selective estrogen-receptor response modulators (SERMs) work by
blocking eﬀects of estrogen in breast tissue by a selective binding to
ERs in breast cells. Tamoxifen is the most commonly used SERM [83].
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Figure 2.2. Molecular mechanisms of tamoxifen resistance and in-
volvement of growth receptors. [139].
2. Aromatase inhibitors (AI) prevent the production of estrogen in post-
menopausal women. AIs exert their function by the blockage of the
aromatase enzyme responsible for converting androgen to estrogen. Be-
cause of the reduction in the availability of aromatase enzyme, less
amount of estrogen is available to bind to the estrogen receptor [133].
3. Estrogen-receptor downregulators (ERDs) block the eﬀects of estrogen
by multiple modes of action. ERDs can either bind to ERs, change
the shape of ERs such that they cannot bind to estrogen or reduce the
concentration of ERs in breast tissue. ERDs are chosen for adjuvant
therapy when the other hormonal therapies do not work. Fulvestrant
(commercial name, Faslodex) is a pure anti-estrogen drug useful for the
treatment of advanced ER-positive breast cancers in post-menopausal
women [83].
4. Luteinizing hormone-releasing agents (LHRHs) work by stopping the
production of estrogen in ovaries. As a result, a very small amount
of estrogen is produced from other sources of estrogen. Such mode of
action is ideal for pre-menopausal patients at early-stage of cancer [177].
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2.3.2 Tamoxifen resistance
Tamoxifen, formerly known as ICI46; 474 was the ﬁrst selective ER regula-
tor (SERM) tested in 1970. Tamoxifen blocks the action of estrogen in the
breast by binding to ER, thereby making them unavailable for binding with
estrogen or with co-activators of estrogen. While tamoxifen blocks estrogen
in breast tissues, it mimics the action of estrogen in other tissues.
Tamoxifen has been shown to be a very eﬀective in reducing the risk
of invasive and noninvasive breast cancer by 49% compared to a group
receiving placebo. The drug has also been shown to reduce the risk for
women suﬀering from LCIS [57]. However, about half of the recurrences
in ER-positive breast cancer are non-responsive to tamoxifen, either via
intrinsic or acquired resistance to the drug. The primary mechanism of
intrinsic or de novo resistance is the lack of ER expression, however,
mutations in genes such as CYP2D6 can signiﬁcantly hinder the activity
of tamoxifen [139, 82]. Acquired resistance to tamoxifen has been widely
studied for the identiﬁcation of molecular mechanims of drug resistance.
Figure 2.2 shows that an aberrant activation of cellular signaling pathways
involving growth factor receptors such as EGFR, ERBB2, IGFR, FGFR
often activate alternative pathways to promote proliferation of breast cancer
cells and inhibit apoptosis [150]. Further, changes in the miRNAs expression
and miRNA-mediated regulation often lead to an aberrant activation or
inhibition of signaling pathways, and thus contribute to the development of
tamoxifen resistance. Roles of miRNAs in the modulation of gene expression
during tamoxifen resistance are studied in detail in paper I (Chapter 6).
An analysis of gene expression proﬁles of tamoxifen-sensitive MCF7/S0.5
cell line and three MCF7/S0.5 derived tamoxifen resistant cell lines is de-
scribed in Chapter 6. I analyzed these arrays for diﬀerential expression
of genes between tamoxifen resistant and MCF7/S0.5. In Table 2.1, genes
associated to various signaling pathways are listed with the cell line in which
they were found to be signiﬁcantly diﬀerentially expressed (abs(log2 fold
change)  0.5 and adj. p-value  0.05).
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Table 2.1. Genes in the tamoxifen resistance pathway neigh-
borhoods. Genes listed in this table were found signiﬁ-
cantly diﬀerentially expressed in the TamR-cell lines (TamR1,
TamR4, TamR8) in comparison to MCF-7/S0.5 (tamoxifen
sensitive) cell line [log2FC  0.5 and adj.p-value  0.05]. The-
ses genes showed associations with signaling pathways known
to be involved in tamoxifen resistance
Cell
line
Direction
of
change
Gene names
TamR1 Up APOD, BMP7, C17orf91, CD59, CDKN2B, CLU,COL5A1, CPE, DUSP6, EFNB2, EPAS1, FZD7, FZD8,
IRF6, ITPR1, LYN, MAGED1, MAP1B, MYO1B, NOG,
NRP1, PCDH8, PLAU, PMEPA1, PRICKLE2, PRKCA,
PRSS23, SDC2, SH3BGRL, TCF7L1, TGFB2, THBS1,
TNIK
Down ARHGEF6, C9orf3, CACNA1D, CAP2, CDH18, EGR3,
ELOVL2, ERBB4, ESR1, GREB1, GULP1, KIAA1324,
MGP, NFKBIA, NPY1R, RBM24, SGK1, SLC3A2,
SULF1, TM4SF1
TamR4 Up ACADL, ARMCX1, ATP9A, C3, CAMK2B, CD36,CITED1, CLIC3, CPE, CPT1C, CTGF, DDX58, EGR2,
EPHA4, FDFT1, FYN, GLA, GRB14, IFI27, IFIT1,
IFNB1, IFNGR1, IL15, IRF7, IRF9, ISG15, JUP,
OASL, PLA2G16, PLCXD3, PMEPA1, PRKD1, PTGES,
RAPGEFL1, RPRM, STAT1, SULF1, TGFBR3, TLR2,
TNFAIP3
Down ADIPOR2, AURKA, AURKB, BAMBI, BCL2L12,
C12orf32, CCNA2, CCNB1, CCND1, CDCA8, CDKN1B,
CENPA, CENPF, CTNNAL1, CXCL12, DLGAP5,
EIF4EBP1, ELOVL2, FOXC1, GAB2, GNB4, GREB1,
GULP1, HMMR, IGF1R, IL6ST, IRS2, KIF23, LIN7A,
MT2A, NCAPD2, NCAPG, NCAPH, NDC80, NEK2,
PCDH7, PCK2, PPM1E, PRKAR2B, RAB11FIP3,
RAB31, RACGAP1, SMC2, SOX3, SVIL, TFAP2C,
TLE1, TPX2, TSPAN5, WWP
TamR8 Up CHFR, COL28A1, CP, BLNK, CALML5, CDKN2B,CROT, EXOC3, FGF13, FZD1, HIP1, IL7, IMPA1,
INPP4B, LEPR, NSUN2, PCDH8, PRLR, SUGT1,
TP53TG1, TPD52, YWHAG
Down BMPR1B, DUSP2, GNB4, ID1, IRS2, OSMR, PPM1E,
SCIN, TFF1

Chapter 3
Lymphomas of the eye
Ocular lymphoma is the lymphoma localized in the eyelids, conjunctiva,
lacrimal gland, intraocular or in the orbital regions of the eye. Although
relatively uncommon, they account for 5-10% of the all extranoda lym-
phomas [60]. This chapter provides a brief introduction to the mucosa
associated lymphoid tissue lymphoma (MALT) and diﬀuse large B-cell lym-
phoma (DLBCL) of eye.
3.1 The eye
An eye consists of many components, as seen in the Figure 3.1. The cornea
and eyelid shield the eye from intense light. The conjunctiva is a mucous
membrane covering the most of the eye. Light enters the eye through the
pupil. The pupil is a hole located in the center of the iris that allows light
to enter the retina. The iris controls the aperture of the pupil. The retina,
located in the inner most part of the eye, contains rod and cone cells that
are capable of the perception of depth and diﬀerentiation of colors [149].
When stimulated with light, the retina initiates a number of chemical and
electronic modules that translate the light into signals that are processed by
the brain. A uvea consists of iris, ciliary body and choroid, the vascular layer
between retina and sclera. The structures adjacent to the eye, such as eyelids,
eyelashes and lacrimal glands and conjunctiva comprise the ocular adnexa.
3.2 Lymphomas of eye
Hodgkin and non-Hodgkin lymphomas originate from lymphocytes, the
white blood cells. In the presence of Reed-Sternberg cells in the lymphoma
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Figure 3.1. Schematic diagram of human eye. [Source:www.
wikipedia.org]
samples, the disease is classiﬁed as Hodgkin lymphoma (HL) and otherwise
it is non-Hodgkin lymphoma (NHL) [101]. The Non-Hodgkin lymphoma
(NHL) is a term used for a variety of lymphomas depending on the age,
grade of tumor, growth pattern and immunophenotypes [181, 88]. NHL is
the most common type of ocular lymphoma. Depending on the site of origin
in the eye, the ocular lymphoma can be either intraocular or orbital adnexal.
3.3 Mucosa-Associated Lymphoid Tissue Lymphoma
(MALT)
The intraocular lyphomas involving retina or uvea are malignant neoplasms.
Ocular adnexal lymphomas (OALs), on the other hand, describe a het-
erogeneous group of malignancies representing 6-8 % of the extranodal
non-Hodgkin lymphomas (NHL) [189, 60]. The mucosa-associated lymphoid
tissue lymphoma (MALT), which is also known as extranodal marginal zone
lymphoma (EMZL) is the disease common among the elderly population.
MALTs are initially indolent in nature and progress slowly, without a man-
ifestations of symptoms for up to a year. The treatment options for OALs
include radiation therapy, radiotherapy, and often a systemic chemotherapy.
However, when untreated, this disease can transform into the malignant
diﬀuse large B-cell lymphoma (DLBCL).
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Pathogenesis of ocular MALT has been linked with antigenic stimula-
tions such as from Chlamydia psittachi. However, there is a great amount
of disagreement between studies, possibly due to the geographical diﬀer-
ences [54, 155, 138, 39, 28, 183]. Recent studies have also implicated a
number of chromosomal aberrations in MALT; for example, API2/MALT1-
(t(11;18)(q21;q21), IGH/Bcl-10 - t(1;14)(p22;q32) and IGH/MALT1 -
t(14;18)(q32;q21) . The t(11;18) has been found more frequently in pul-
monary and gastrointestinal MALT lymphomas, whereas t(14:18) is the
most frequent translocation in ocular MALTs [179].
3.4 Diﬀuse Large B-cell Lymphoma (DLBCL)
Swerdlow deﬁnes DLBCLs as a neoplasm consisting of a diﬀuse growth
pattern of large neoplastic B cells with nuclear size equal or twice that of
normal lymphocytes or equal to or larger than the size of normal macrophage
nuclei. Like MALTs, DLBCL usually occurs at an average age of 70 years,
but the disease has been seen in adults as well as children. [181]. DLB-
CLs involving ocular adnexal regions are rare, comprising of 13% of ocular
adnexal lymphomas [55, 169]. A standard treatment option for DLBCL is
CHOP, a therapy that is a combination of chemotherapy, steroids such as
rituximab and a monoclonal antibody.
DLBCLs are quite heterogeneous in terms of morphology, immunophe-
notypic, cytogenic and genetic proﬁles. An immunohistochemical expression
of CD10, Bcl2, Bcl6 and MUM1 is often used together with gene expres-
sion proﬁling to classify DLBCL into, activated B-cell-like (ABC), germinal
center B-cell like(GCB) or non-GCB types, depending on the similarity of
gene expression to germinal center B cells and chromosomal translocations
involving BCL2/IGH locus. FOXP1 gene has been characterized as a marker
of ABC, whereas ampliﬁcation of miR-17-92 cluster and deletion of tumor
suppressor PTEN have been linked with the GCB subtypes [110] . Classiﬁca-
tion of DLBCLs into distinct subgroups is commonly done to understand and
deﬁned underlying genetic mechanisms and to decide diﬀerent therapeutic
options.

Chapter 4
Measuring gene expression
Transcriptome is the term often used to describe a set of transcripts present in
a given organism, tissue type, developmental stage or physiological condition.
The types of RNA transcripts covered by transcriptomics include mRNAs,
small RNAs such as miRNAs, piRNAs, siRNAs, snoRNAs etc., as well as
long noncoding RNAs. In order to understand transcriptomics and gene
regulation events involving various RNA species, it is necessary to quantify
set of transcripts in the cell corresponding to a physiological condition or stage
of an organism. Various technologies have been developed for the discovery
and quantiﬁcation of these transcripts. This chapter brieﬂy describes some of
technologies and platforms as tools of measuring gene and miRNA expression
for the projects included in this thesis. I begin with an introduction of the
microarray technology and describe both, gene and miRNA expression array
platforms. qPCR technologies with the focus on Exiqon’s miRNA qPCR are
also discussed. Lastly, the small RNA-seq technology and Illumina platform
are discussed .
4.1 Microarray technologies
The microarray technology works with the basic principle of hybridization
between two complementary nucleic acid sequences. Fluorescence labeling of
the samples is used to detect and quantify the amount bound. As opposed to
Northern blots, microarrays oﬀer a high throughput detection of transcription
of thousands of genes simultaneously. Several methods based on such concept
have been reported [19, 118, 184], but the most successful among them is
the DNA microarray technology, implemented as oligonucleotide or spotted
arrays [164].
Oligonucleotides (oligos) are the short DNA sequences (20-60nt) that are
designed to match speciﬁc regions of genes. When oligos are printed or in situ
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synthesized on solid surfaces, such as glass or silicon using photolithography
and combinatorial chemistry, they are referred to as in situ synthesized
oligonucleotide arrays. Spotted arrays, on the other hand, are prepared
using a robotic array printers to “spot” small amounts of probe to desired
location on the array. As the technology has evolved, a number of vendors
such as Aﬀymetrix, Agilent, Roche, Exiqon, etc. provide services for gene
expression proﬁling of protein coding and non-coding genes. For this thesis,
Exiqon’s LNA microRNA microarrays and Aﬀymetrix GeneChip Human
Genome U133 Plus 2.0 arrays were used. In the following sub-sections, I will
discuss both of these platforms.
Exiqon miRCURY array platform
Speciﬁc detection of microRNA expression is particularly diﬃcult due to
their short lengths, heterogeneous GC content (20-90%) and the wider range
of melting temperatures (Tm) for their nucleic acid duplexes. To complicate
the matters further, an extremely high sequence similarity between miRNAs
of the same sequence family also makes the design of oligos diﬃcult. Using
Locked nucleic acid (LNA), a proprietary technology from Exiqon, the RNA
nucleotide is modiﬁed such that the thermal stability of the oligonucleotide
duplex increases signiﬁcantly. This technology also provides high melting
temperatures (Tm) to the LNA probe-miRNA duplexes at high sensitivity
and high speciﬁcity.
Exiqon’s 5th generation miRCURY LNA arrays oﬀer capture probes for
all miRNAs in human, mouse, rat and related viruses from miRBase release
version 14 [68] and control probes. Each array consists of 12 sub-arrays in
4 replicates. The spot sizes are 105m and the distance between spots is
250m. More than 890 human, mouse and rat mature miRNAs and spike-in
controls are spotted four times on the array. The arrays can be run either
as dual-color using Hy3 and Hy5 labeling dyes or as single color (Hy3 only).
Typically, total RNA from sample is isolated and puriﬁed using Exiqon’s
miRCURY RNA isolation kit. Hy3 (Cy3) is normally used to label the sam-
ples because it is less prone to ozone quenching compared to Hy5 (Cy5) [52].
For a common reference design where the reference is made by pooling
of all samples in the study or a universal reference, the sample should be
labeled with Hy3 and the reference with Hy5. Next, the labeled samples are
mixed and hybridized onto pre-spotted miRCURY LNA microarrays in their
hybridization chamber. After following an overnight hybridization, the slides
are washed and scanned using Agilent G2505B scanner. The scanned images
are then exported for data analysis such as pre-processing, normalization
and further analyses.
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Figure 4.1. DNA microarray protocol for Aﬀymetrix microarrays
[Source : Aﬀymetrix].
www.aﬀymetrix.com
Aﬀymetrix GeneChip Human Genome U133 plus 2.0
The Aﬀymetrix GeneChip Human Genome U133 plus 2.0 array covers more
than 38; 000 human gene clusters (Unigene) encoding for more than 45; 000
transcripts represented by about 54000 probe sets and 1:3 million 25-mer
oligonucleotide probes. These probes are in situ synthesized to glass sub-
strate by a combination of photolithography and combinatorial chemistry.
The probes are derived from reference sequences from GenBank (NCBI,
March 2003), dbEST (NCBI, February 2003), RefSeq (NCBI, March 2003)
and NCBI human genome assembly, Build 31 [1]. Probe sequences are
selected from 600 bases downstream to the 3’ end of each transcript and are
chosen to be unique to avoid nonspeciﬁc hybridizations as much as possible.
To prepare the sample for hybridization, mRNA is extracted, reverse
transcribed to cDNA, in vitro transcribed (IVT) to cRNA, biotin labeled
and fragmented. The fragmented cRNA is then left to hybridize to the
array overnight (Figure 4.1). The hybridized array is then stained with a
ﬂuorescent dye, such as biotin, and on the next day it is washed and scanned
via Aﬀymetrix GeneChip Scanner 2000 [2].
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Figure 4.2. Exiqon miRNA qPCR protocol. Template RNA is ﬁrst
diluted in nuclease free water and later mixed with RT master mix and
left for incubation to obtain cDNA. Next, the previously prepared cDNA
is mixed with SYBR Green master mix, primers and added to the PCR
plates. Ampliﬁcation is continuously monitored for 45 PCR reactions
on LightCycler480 system. [Source: Exiqon A/S].
4.2 Real-time qPCR technology
Quantitative polymerase chain reaction (qPCR) technologies oﬀer a means to
measure the abundance of genes at higher sensitivity of detection compared
to other technologies such as northern blotting, RNAse protection assay
or microarrays [41, 178, 66]. For microRNAs, where even a small change
in expression level might be of biologically signiﬁcance, a higher detection
sensitivity from using qPCR technology is especially very useful.
In the real-time quantitative PCR (RT-qPCR) assay, accumulation of
PCR product is measured over number of PCR cycles. The time point at
which the concentration of the PCR product reaches a certain threshold
level, is recorded as Cp (crossing point) or Ct (cycle time), depending on the
qPCR manufacturer. In theory, the exponential ampliﬁcation of template X
at any given cycle n is written as:
Xn = X0  (1 + EX)n (4.1)
where Xn is the number of copies of the template at cycle n, X0 is the initial
number of copies of the template and EX is the ampliﬁcation eﬃciency.
Ideally the ampliﬁcation eﬃciency is 100%, but in practice, it is not likely
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Figure 4.3. Ampliﬁcation plot for hsa-let-7i number of qPCR re-
actions performed on LightCycler 480. Fluorescence measured using
SYBR Green I is plotted for each replicate within cell line clones, MCF7,
TamR1, TamR4 and TamR8. Dotted x intercepts represent the re-
ported Cp values.
to achieve 100% ampliﬁcation eﬃciency due to cross-contamination, thermal
damage to template or also poor primer chemistry [158, 15]. Therefore, PCR
eﬃciency is often measured by ﬁtting a linear regression on data obtained
through a dilution series.
Nevertheless, since the ﬂuorescence is proportional to the amount of PCR
product, the extent of ampliﬁcation can be plotted with respect to cycle
number as shown in Figure 4.3. The PCR cycle is shown on the x-axis and
ﬂuorescence from the ampliﬁcation reaction on y-axis. Initially, ﬂuorescence
remains at the background level and increases exponentially depending
on the ampliﬁcation eﬃciency. In our example, Cp values are marked by
intercepts on x-axis. If the template amount present at the start of the
reactions is too low, more number of cycles will be required for the ﬂuo-
rescence to reach a speciﬁc level. Thus the reactions will have high or late Ct.
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Exiqon’s miRNA qPCR platform was employed for the tamoxifen resistance
project .
Exiqon’s miRCURY LNA Universal miRNA qPCR
Exiqon’s ready-to-use Human Panel I and II, V2.R plates (product number
203608) consist of LNA miRNA PCR primer-sets that are pre-aliqoted to
384 well plates. The set of primers include more than 365 LNA primers
for miRNAs, 6 primer sets for reference genes (U6snoRNA, SNORD38B,
SNORD49A, miR-103, miR-191 and miR-423-p), 3 inter-plate calibrators
(UniSp3 IPC) and 1 RNA spike-in control primer set. Inter-plate calibrators,
pre-aliqoted on both panels, are used for calibration between PCR plates.
Standard deviation between IPC replicates must not exceed 0.5. Calibration
factor is deﬁned as the diﬀerence between plate mean for IPC replicates and
a global mean of IPCs from both plates. Each plate is then individually
calibrated by subtracting the calibration factor from all values in the plate.
The experimental protocol consists of two steps: ﬁrst-strand cDNA
synthesis and real-time PCR ampliﬁcation. A polyA tail is added to the
mature microRNA template. The polyA tail acts as a template for binding
of universal RT primer (polyT) for the reverse transcription (RT) step ,
The cDNA template is then ampliﬁed using microRNA speciﬁc forward and
reverse LNA primers. Exiqon’s miRNA qPCR assays were employed to
proﬁle miRNAs in the cell line model described in Paper I and the analysis
techniques
4.3 RNA-seq technologies
Microarray and qPCR technologies, as described earlier, require knowledge
of the genome a priori. In contrast, sequence-based approaches determine
the cDNA sequence during the process, therefore not requiring the knowledge
of the genome a priori. Sequencing approaches have existed for long time.
Initial approaches were low-throughput, expensive and often not quantita-
tive [63, 13]. Few years later, new methods such as serial analysis of gene
expression (SAGE) analysis of gene expression [184] and massively parallel
signature sequencing (MPSS) [147] were developed. These approaches al-
lowed a precise quantiﬁcation of gene expression. Sanger sequencing on the
other hand was time-consuming and was unable to detect rare species and
short species due to the limited sequencing depth [129]. Small RNAs such
as miRNAs, siRNAs, piRNA, etc. are relatively hard to detect due to their
low concentration in cell. Fortunately, with the advent of high-throughput
sequencing technologies, it has now become possible to map and quantify
small RNA transcriptomes via small RNA-seq approaches.
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RT-PCR cycle 14
RT-PCR cycle 1
RT-PCR cycle 2
RT-PCR cycle 3
Sequencing
Illumina Genome Analyzer IIx
Figure 4.4. Illumina Solexa small RNA-seq protocol version 1.5.
A number of vendors, including Illumina, Applied Biosystems SOLiD and
Roche 454 provide solutions for RNA-seq studies. I have analyzed single-end
small RNA-seq dataset generated by employing lllumina sequencing to MCF7
and three MCF7-derived tamoxifen resistant cell line clones. In Chapter 5,
analysis of small RNA-seq data and challenges in drawing statistically sound
conclusions are discussed.
Illumina small RNAseq library preparation protocol
A typical small RNA library preparation begins with the isolation and
puriﬁcation of template RNA. As per Illumina’s small RNA library prepara-
tion protocol version v1.5[86], sequencing libraries are prepared by ligating
speciﬁc adapters on the 5’ and 3’ ends of the RNA molecules. The adapter
ligated sequences are then reverse transcribed and ampliﬁed by PCR to
increase the size of the library. The ampliﬁed library is then deep sequenced
(Figure 4.4) on a single lane of an Illumina Genome Analyzer ﬂow cell.

Chapter 5
Methods for the analysis of gene
expression
The goal of data analysis is to highlight useful information hidden in the
high-throughput gene expression datasets by inspecting, preprocessing, nor-
malizing and modeling of data. This chapter brieﬂy summarizes methods for
the analysis of gene expression data obtained through microarrays, qPCR and
sequencing technologies described in the previous chapter. Small RNA-seq
and miRNA qPCR are compared in the later part of this chapter. Finally,
an adaptive implementation of gene shaving, an unsupervised method of di-
mension reduction is described with the help of a DLBCL dataset.
5.1 Analysis of gene expression arrays
Various gene expression proﬁling techniques described earlier in this thesis,
have made it possible to do high-throughput analysis of the abundance of
transcripts. However, these experiments suﬀer from various technical biases
that may hamper the detection of the real biological variance between the
samples to be compared. Changes in the ﬂuorescence of the dyes used, scan-
ner settings, misaligned grids or spatial patterns introduced by the liquid
diﬀusion patterns, etc. contribute to the technical variation. Therefore, as a
ﬁrst step of the data analysis, it is necessary to remove such technical biases
by applying various preprocessing and normalization methods. These meth-
ods may diﬀer based on the microarray platform used. All of the methods
and analyses described here are relevant to the projects during my PhD and
were carried out in R [143] environment, unless speciﬁed otherwise.
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Figure 5.1. Array images from two-color array. Spatial variation of
background (green channel) is evident and should be removed through
background correction method.
Preprocessing and normalization methods for gene
expression arrays
First step after scanning of microarrays is to assess the quality of arrays by
visualization of intensities and spatial trends on each array. In case of spotted
dual-channel microarrays, such as Exiqon’s LNA miRNA microarrays, image
analysis software records morphological details such as spot perimeter, area,
location and heterogeneity measures such as standard deviations across the
pixels used to construct the foreground and background intensities. Many
of these tools mark poor quality spots using a practice commonly known as
“ﬂagging”. However, when importing the image ﬁles into the R environment
for data analysis, one can manually ﬂag poor quality spots based on the
observed diﬀerences between reported mean and median intensities for each
channel separately. For example, we used a custom function that ﬂags probes
if the foreground mean and median from GenePix for a given spot diﬀers by
a threshold, 50.
myfun <  function (x , threshold=50) {
okred <  abs(x[ ,”F635 Median”] x[ ,”F635 Mean”]) < threshold
okgreen <  abs(x[ ,”F532 Median”] x[ ,”F532 Mean”]) < threshold
as . numeric(okgreen & okred)
}
rawDat <  read .maimages( in f i l e s , source=”genepix .median” , wt. fun=myfun)
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Flagging does not have any eﬀect on the intensity of spots. However, during
normalization it is possible to keep these spots from aﬀecting other good
quality probes.
Background correction and normalization
In addition to the spot morphology related details, an image analysis software
also returns foreground signal intensities and local background intensities for
each spot on the array. In case of two-channel microarrays, the same is
returned for each channel. The foreground signal measures the intensity for
each spot, while background intensities relates to the noise that corresponds
to nonspeciﬁc hybridizations or spatial biases on the chip. In order to obtain
correct estimates of signal intensities, background correction methods are
applied. (Figure 5.1). The traditional background correction method works
on a simpliﬁed assumption that background intensities Rb andGb are additive
to the measured foreground intensities, Rf and Gf , respectively. Therefore,
the background corrected intensities R and G can be obtained as Rf   Rb
and Gf   Gb, respectively. However, when the background intensities are
higher than the foreground, corrected intensities are often negative or highly
variable for low intensities spots [14].
We chose to apply normexp method for background correction in the
microarray datasets used for Paper I and Paper II. The method is based on
normal plus exponential convolution model as described by McGee et al [130]
and used in RMA normalization method by Irizarry et al [87]. The model
assumes that the observed foreground intensities result from a convolution of
true signal that is exponentially distributed, and the background noise that
has a normal distribution. In case of two-color array, convolution method
is applied to each channel separately. Normexp + offset method adds a
constant oﬀset to the corrected intensities such that the values are pushed
away from zero and variance is reduced. Normexp used for my thesis has
been implemented in limma package [170, 171] .
Next step after background correction is to apply normalization. Normaliza-
tion adjusts for the technical artifacts resulting from microarray technology
rather than biological diﬀerences between individual genes or samples. Nor-
malization is applied to the background corrected log-ratios of expression,M .
M = log2(R/G) (5.1)
The log intensity of each spot is written as,
A = 1/2(log2R+ log2G): (5.2)
One of the most common normalization strategies, central tendency (e.g.
mean, median) normalization takes the global mean/median as the baseline
or reference for normalization. The global mean/median is subtracted from
intensities of each array. Such methods based on a global measure often
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perform poorly in case of microarrays. One of the reasons for this eﬀect is the
signal dependence, requiring a signal dependent and non-linear normalization
approaches. The most commonly used non-linear normalization methods
are loess normalization, qspline and quantile normalization. For quantile
normalization (implemented in RMA by Irizarry et al. [87]), the highest value
from each array is replaced with mean of highest values, second highest value
replaced by mean of second highest values, and so on. This method forces
distributions of all arrays to be equal. This may not be a good normalization
strategy when the arrays represent diﬀerent biological conditions and as-
sume vastly diﬀerent distributions coming from biological signal. Loess and
qspline normalization method apply a loess or cubic-spline ﬁt to the average
intensities on the array [190]. Qspline normalization introduces fewer errors
and is more robust than loess normalization. Between-array normalization
may sometimes be needed when there are substantial diﬀerences in the scale
between arrays. A median absolute deviation method scales M-values of a
series of arrays such that each array as same median absolute deviation.
Principal component analysis
Principal component analysis (PCA) is a frequently used procedure for di-
mensionality reduction of the data while retaining most of the variation in
the data set. The principal components refer to the direction in which the
variation in data is maximal. This method is mainly used to identify simi-
larities between sample types or to determine grouping of data based on thee
major patterns of gene expression. As outlined earlier, high-dimensional data
sets can be visualized in three-dimensions by projecting samples onto the top
principal components. In the R environment, PCA has been implemented as
singular value decomposition (SVD) of the data matrix. In my thesis I used
PCA for visualization of high dimensional gene expression data as well as for
clustering of gene expression data.
5.2 Preprocessing and analysis of miRNA qPCR
datasets
Melting curve characteristics
Exiqon recommends SYBR Green, a DNA-binding dye to detect the amount
of ampliﬁed PCR product. SYBR Green ﬂuoresces when it is bound to
double-stranded DNA (dsDNA), including non-speciﬁc reaction products,
called primer-dimers. To detect the existence of any non-speciﬁc bindings,
a dissociation characteristic of the double stranded DNA is obtained as a
post-PCR step.
The temperature at which a DNA strand denatures or separates when
subjected to high temperatures depend upon the base composition, length
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Figure 5.2. Melting curve characteristics of two miRNA PCR primers.
of the sequences and the GC content of the strand. Therefore, even a
small contamination in the assay may artiﬁcially increase the ﬂuorescence
and make it impossible to exactly quantify the amount of template after
ampliﬁcation.
Dissociation characteristics are obtained by changing the temperature in
small increments while monitoring ﬂuorescence at each step. An increase
in the temperature results in denaturation or melting of dsDNA, at which
the ﬂuorescence decreases. During cooling, the ﬂuorescence increases as
the PCR products re-anneal. The negative ﬁrst derivative of the change in
ﬂuorescence over a change of temperature is plotted as shown in Figure 5.2.
Melting temperatures (Tm) of the samples are displayed as peaks in the
melting curves and they were identiﬁed using an R implementation of the
method described by Coombes et al. [34]. This plot represents two scenarios
in which the melting curves show multiple peaks or a single peak relating
to non-speciﬁc or primer-speciﬁc binding of PCR products to SYBR Green
respectively. Replicate assays for miR-222 show single and unique peak
occurring around 70C, whereas miR-518f replicates have multiple peaks.
As a result, miR-518f assay is removed or ﬂagged as poor quality assay.
Allowing multiple peaks for an assay increases the standard error of mean,
SEM, calculated over a set of replicate assays (Figure 5.3).
qPCR normalization methods
As with the microarrays, normalization of qPCR data is performed with a
goal of distinguishing technical variation from true biological variation. The
gold standard strategy of qPCR normalization relies on a set of candidate
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Figure 5.3. Relationship between number of peaks in melting curve
characteristics and standard error of the replicate mean. A clear single
peak in the melting curve characteristics decreases the probability of
error.
reference genes, also called housekeeping genes. These genes are either
pre-selected on the basis of their non-variable expression across various
experimental conditions in large-scale studies, or chosen by following a bioin-
formatic analysis described by [182]. However, in case of high-dimensional
datasets, such as miRNA qPCR dataset, use of the all data points for nor-
malization reduces technical variation between replicates, as described by
Mestdagh et al. [131].
For the miRNA qPCR dataset, consisting of four cell lines, each with
three replicates (Paper I, Chapter 6), I calculated standard error of mean
(SEM) for each individual miRNA across all samples within the same cell
line group. As depicted by Figure 5.4, in an unnormalized dataset, raw mea-
surements with higher Cp value have high SEM. An aim of normalization
is to reduce the technical variance, modeled as SEM. I applied a series of
normalizations on this dataset to assess the eﬀectiveness of a normalization
method at reducing the standard error. The following normalizations were
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applied : house-keeping gene mean/median normalization, global mean/-
median normalization and qspline normalization described in Workman
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Figure 5.4. Standard error of replicate mean as function of Cp value:
Before normalization. Higher variabliity among replicate measurements
is noticeable at higher Cp values
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Figure 5.5. Standard error of replicate mean as function of Cp value:
After normalization. Normalization is eﬀective at reducing the standard
error of means, especially for lower range of Cp values
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Figure 5.6. Eﬀectiveness of normalization methods in reducing tech-
nical variation between replicates.
et al. [190]. SEMs were calculated for every miRNA across all replicates
within each cell line group. Distributions of the relative SEMs are shown
in Figure 5.6. As evident from the ﬁgure, both global mean and qspline
method oﬀer the highest reduction in SEMs and do not introduce additional
variance as house-keeping gene based normalization methods. The eﬀect of
normalization can be seen in Figure 5.5 as reduction in variance among the
replicates.
5.3 Statistical testing
Dealing with high-throughput data consisting of variety of sample types and
biological or technical replicates requires appropriate statistical methods. In
biology, it is often required to detect the diﬀerences in expression between
two or more conditions. The ﬁrst and most simple method used to compare
two conditions was the use of fold-changes [29], however, this method did
not take the variance within groups into the consideration and therefore, it
was of limited use. Methods such as ordinary t-test [42] assume the null
hypothesis that the diﬀerence in the means of two groups to be compared
is zero. t-test is performed on a gene-by-gene basis. When testing multiple
genes using t-test, the probability of error increases.
Many experiments often need to compare more than two groups at a
time. In these cases ANOVA can be used to identify diﬀerentially expressed
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genes between more than two conditions. In contrast with t-test, ANOVA es-
timates the variability within group based on information borrowed from all
the groups in the comparison, giving more statistical power and sensitivity
compared to the t-test. However, both t-test and ANOVA are paramet-
ric and make an assumption of normality and independence of variables.
Wilcoxon rank-sum test (used in Paper I), on the other hand, is one of
the non-parametric tests that makes no assumptions about distribution of
data [188].
A method by Smyth et al [170], implemented as a Bioconductor package
limma, applies a linear model to each gene. The model is designed according
to the supplied experimental design and sets of independent variables or
conditions to be compared. The coeﬃcients of the ﬁtted models describe
the diﬀerences between groups. This method is extremely useful as it is
applicable to microarrays as well as qPCR datasets. With a well designed
model, the method handles technical probe replicates as well as biological
replicates in a block design. For this thesis, the limma approach has been
used to compare diﬀerent experimental conditions.
Number of simultaneous hypothesis testing calls for a multiple testing
correction. Several methods for multiple testing correction have been devel-
oped, in which Bonferroni and Benjamini Hochberg [7] methods are the most
conservative. I have used Benjamini Hochberg method of multiple testing
correction throughout this thesis.
5.4 Preprocessing and analysis of small
RNA-sequencing data
Read quality control
Raw reads are received in the ﬁles formatted using FASTQ format as shown
in 5.7. FASTQ format is widely used to standard format to store the read
sequences and Phred quality scores in the same ﬁle [33, 50]. Although Illu-
mina sequencing uses diﬀerent quality scoring, the ﬁle format looks similar
Figure 5.7. Example of fastq ﬁle
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Figure 5.8. Per base quality report generated for raw fastq ﬁle using
FastQC.
to FASTQ. A typical FASTQ block allocates four lines per sequence. Line 1
begins with @, and is followed by a sequence identiﬁer. Line 2 contains raw
sequence letter. This line is followed by a + sign, and an optional sequence
identiﬁer (encoded in Illumina FASTQ ﬁles). Line 4 contains quality scores
in encoded in ASCII.
Phred quality score is a non-negative integer that represents error prob-
ability of a base call to be wrong. Therefore, a Phred quality score Q is
written as :
Q =  10  log(err)/log(10) (5.3)
where err is the error probability of a base. Thus, to allow error probabilities
up to 0.01, the minimum Phred quality score required is 20. Quality scoring
in Illumina/Solexa raw ﬁles is slightly diﬀerent. Illumina/Solexa quality
score sQ is given by
sQ =  10  log(err/(1  err))/log(10): (5.4)
Since various alignment algorithms assume Phred quality score to assess
quality of base call, we converted Illumina/Solexa scores into Phred scores
using a Python script.
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Figure 5.9. Eﬀect of trimming low quality bases. Per base quality
report generated for fastq ﬁle using FastQC.
Using a quality control tool, FastQC [165], I generated quality control
reports on the reads. Figure 5.8 depicts a distribution of base quality scores
over one FASTQ ﬁle. The quality of base typically declines toward 3’ ends
of the read. Base errors may cause mapping errors since many aligners rely
on read-quality score for generating best quality mappings. Therefore, in
order to achieve reliable alignments and to reduce the probability of false
positives, I trimmed the 3’ ends of reads and quality scores. Distribution of
quality base scores after the trimming of low-quality bases can be seen in
Figure 5.9.
Other parameters such as per base sequence quality, sequence length dis-
tribution and sequence over-representation were also assessed using FASTQ.
Trimmed reads of lengths shorter than 15 bases were removed. Over-
represented reads were assess for a match with the adapter sequences used
during the library preparation. Reads that map adapter sequences were
removed. After the preprocessing steps, the number of clean reads corre-
sponds to about 99% of the total reads. The set of clean reads was heavily
duplicated, as elucidated in Table 5.1.
Read alignment
Alignment is the process by which sequencing reads are aligned to a reference
genome or transcriptome. We were particularly interested in diﬀerential ex-
pression of miRNAs between tamoxifen-resistant and tamoxifen-sensitive cell
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Table 5.1. Summary statistics on sRNA-seq reads
Cell line RNA
grams
Total
Reads
Clean
Reads
Unique
Clean
Reads
% of read-
duplication
in unique
clean reads
MCF7 36.912 11086223 11045089 345512 3.13
TAMR1 36.192 11334364 11296849 311877 2.76
TAMR4 35.088 11080176 10954570 467677 4.2
TAMR8 29.616 12207743 12169298 447376 3.68
lines. Various tools for aligning RNA-seq data are available, such as BWA
(Burrows Wheeler transformation-based tool by [114, 115], Bowtie [105],
Novoalign (www.novocraft.com), MAQ [116], to name the few. However,
alignment of small RNAseq has its own challenges. Reads from small RNA-
seq are shorter and miRNA-species to which the reads are mapped, are
known for nearly high-sequence similarities in the seed-regions. Further,
RNA editing [12, 191] in miRNAs can also cause some reads not to map the
genome. Allowing mismatches also increases the chance of multi-mapped
reads. Further, the problem of handling multi-mapped reads require a careful
consideration. Some researches choose to exclude the multi-mapped reads
from the analysis [157] to avoid running into a further problem of allocating
those reads between possible source loci. On the other hand, when multi-
mapped reads are not excluded from the analysis, allocation of these reads
to multiple loci could be weighted in proportion of the number of uniquely
mapped reads at each loci [113, 137].
We applied a diﬀerent approach of handling read alignment as described
below:
1. Trim low quality (Phred score < 20 ) bases at the 3’ read-ends of reads
based on fastq ﬁles.
2. Remove reads of length shorter than 15bp.
3. Generate a dictionary containing distinct read sequences (unireads).
Record the copy number, cn of each unique read sequence. Let us call
the unireads u, where u 2 U .
4. Discard reads with cn = 1, as they might have resulted from sequencing
errors.
5. Generate fasta ﬁles from unireads.
6. Prepare reference database to map the reads against Human precursor
miRNA sequences obtained from miRBase [68] release September 2010.
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7. Alignment of unireads to reference database. No gaps or mismatches
were allowed. Minimum length of alignment = 15.
8. Discard unireads that map to multiple miRNAs (multi-mapped reads).
9. Count number of unireads M , mapped to each miRNA, i.
10. Quantify expression of each miRNA in terms of read counts. Expres-
sion ei for each miRNA is obtained as follow:
ei =
X
M
i=1ui  cni (5.5)
After experimenting with several aligners, I chose to employ BLAT stan-
dalone version 34 [94]. The readcounts per miRNA were obtained as outlined
earlier.
Table 5.2. Summary of RNA-seq alignment
Cell line Input
unireads
(cn>1)
count
uniread
(cn>1)
Aligned
Percentage
aligned
MCF7 83171 17695 84.87
TAMR1 78068 16163 84.21
TAMR4 118133 16957 81.47
TAMR8 115957 17067 81.20
Normalization in small RNA-seq datasets
Current status of RNA-seq normalization methods is relatively less mature
compared to microarray technologies. However, it often involves adapta-
tions from normalization strategies from microarray ﬁeld. For example, the
concept of housekeeping genes in microarrays translates to rank-invariant
sRNA sequences that can help in establishing a baseline for normalization
methods [18]. Spike-in control RNA is often added to the RNA library
during the RNA preparation process, as followed by Fahlgren et al. [51].
Reads that were observed in a single copy are often removed from the
dataset to eliminate outliers caused by sequencing errors. Most commonly
used normalization method in small RNA-seq is to apply linear scaling by
using “library size“ as the normalization baseline. Tools such as DESeq
and EdgeR apply sophisticated methods to measure diﬀerential expression
between sample groups[153, 4]. In the absence of replicates for MCF7/TamR
cell lines, log2 foldchanges calculated by DESeq were close to the log-ratios
of read counts in comparisons.
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5.5 Small RNA-seq versus miRNA qPCR
Each technology has its pros and cons. Small RNA-seq provides an unbi-
ased view of the small RNAs in a biological sample. Unlike microarrays or
qPCR, sequencing does not require the knowledge of the genome a priori,
and therefore the discovery of novel noncoding RNA species is possible.
Sequencing also oﬀers a wider dynamic range compared to qPCR. Due to
all the promises made by sequencing, miRNAs in breast cancer cell lines
(MCF7/S0.5, TamR1, TamR4 and TamR8) were proﬁled using Illumina
small RNAseq, however without replication. We had an opportunity to
compare miRNA qPCR results with those from small RNA-seq experiment.
Before going into the details, It is important to note that the miRBase
version to which reads were aligned to was identical to miRBase version on
which qPCR primers were designed. An intersection of miRNAs detected by
both technologies were investigated for their agreement. Raw read counts ob-
tained from the procedure described in earlier in Section 5.4 were compared
with the Cp values in corresponding cell line groups. Individual comparisons
with their correlations (calculated as Pearson‘s correlation coeﬃcient, PCC)
in each cell line are shown in Figure 5.5. An overall correlation of -0.71 across
all samples was observed. As evident from the ﬁgure, reads with low read
counts corresponds to high Cp values, and miRNAs with high abundance
generally corresponds with low Cp values, with few outliers.
Overlap of diﬀerentially expressed genes from qPCR and sequencing
showed poor agreement. As shown by Figure 5.11, agreement of fold-changes
between corresponding cell line-based contrasts (i.e, TamRx vs. MCF7 sug-
gests poorer correlation PCC values 0.46 for TAMR1, 0.50 for TAMR4 and
0.56 for TAMR8.
In absence of replicates for sequencing dataset, it was diﬃcult to assess
the signiﬁcance of log-ratios of diﬀerential expression, therefore a number
of miRNAs detected by sequencing were not detectable using qPCR. For
example, miR-452 with the log-ratio of  2 in TamR1 vs MCF7 contrast,
was not measurable using qPCR. A similar trend was seen in other cell
line contrasts in RNA-seq data : miR-1293, miR-206, miR-1180, miR-449c.
These miRNAs, although showing diﬀerential expression in RNA-seq were
not at all detectable by qPCR. Once again, in the absence of replication in
RNA-seq experiments, it is hard to state whether or not the miRNAs with
diﬀerential expression in RNA-seq were false-positives.
In summary, I would like to state that despite of promises of high speci-
ﬁcity and sensitivity, and obvious pros of using sequencing technology to
proﬁle miRNAs, it is extremely important to make careful choices for the
experiment design, number replicates, library preparation protocol, prepro-
cessing and normalization method for data analyses steps.
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Figure 5.10. Correlations between miRNA expression levels from
qPCR and small RNA-seq. x  axis refers to mean Cp values within a
cell line and y axix refers to raw read counts for the corresponding cell
line. Values of Pearson correlation coeﬃcients are indicated in the title.
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Figure 5.11. Correlation of miRNA fold changes measured via Ex-
iqon’s qPCR and Illumina’s small RNA-seq technologies. Fold changes
measured through RNAseq are denoted using preﬁx “dge”, whereas those
measured through miRNA qPCR are preﬁxed by “qPCR”. Blocks above
the main diagonal shows distributions of fold changes as 2D histograms,
whereas blocks below the main diagonal represent Pearson Correlation
Coeﬃcients for corresponding comparison
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Figure 5.12. miRNA and sample subgroups identiﬁed by applying
gene shaving to miRNA-expression data
5.6 Searching for patterns within expression data
Clustering technique is commonly applied to gene expression array data
for grouping sets of genes or samples together according to their expression
patterns. Although the classical methods, such as hierarchical clustering,
provide a unique reordering of genes that deﬁne subgroups of genes or sam-
ples with unique expression patterns, but it loses the ﬁner structures within
the data. In 2002, Hastie and Tibshirani [78] developed “gene shaving”, a
two-way clustering method that can ﬁnd ﬁner structure in data and pos-
sibly overlapping clusters using supervised or unsupervised approach. The
method works as follows. Initially, each row of a gene expression matrix, X,
is centered to have zero mean. Singular value decomposition is applied and
inner product of each row in X and ﬁrst principal component is calculated.
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Fraction number of genes, called “shaving factor” (typically 7-10%) having a
lowest inner product to the leading principal component are “shaved” from
the data. This process is repeated until a single gene remains. One of the
gene-block of size k is selected from the nested sequence of gene clusters by
using an optimizing criteria, usually a gap statistic.
I acknowledge the possibility that the ﬁrst principal component may not
always explain all of independent variables, and therefore removing genes
on the basis of their covariance to only the ﬁrst component might be risky.
Therefore, we slightly modiﬁed the original method in following manner.
• Instead of computing inner products to only ﬁrst principal component,
we calculate inner products to ﬁrst three components,
• The termination criteria for gene shaving is adaptive : iterations end
when a geneset showing a threshold amount of variance remain. In
other words, the algorithm terminates when it starts removing more
informative genes that have higher inner product with the leading prin-
cipal components, and
• We reduce the proportion of genes removed at each iteration; value for
the shaving factor is reduced after a speciﬁc number of iterations has
passed without termination (20 iterations).
Signiﬁcance of the clustering result is tested with 100 random permutation
tests by changing the row labels of X.
I was particularly interested in ﬁnding miRNA signatures that might
help in deﬁning groups of samples that may correspond to speciﬁc set of
clinical characteristics. Therefore, this method was applied to a miRNA
expression dataset consisting of 25 ocular DLBCL patient samples described
in Paper II. Figure 5.12 shows a reduced set of miRNAs obtained through
the application of an adaptive gene shaving procedure on this dataset. As
evident from the heatmap, ﬁner structures within this reduced dataset is
characterized by high variation across samples and high correlation across
genes. Sample subgroups were obtained on the bases of clusters of miRNAs
showing similar signatures 5.13 and they were used to characterize groups
of patient samples. Survival analysis on the sample subgroups deﬁned by
miRNA signatures did not provide any signiﬁcant correlation to survival.
This might be due to the limited number of samples (n=25) and a rather
short clinical history of the elderly patients. No signiﬁcant enrichment of the
clinical characteristics within the subgroups was found.
In summary, although very successful in identifying ﬁner structures
within the data, application of this method to a small patient dataset with
heterogeneous clinico-pathological and molecular characteristics did not yield
48
CHAPTER 5. METHODS FOR THE ANALYSIS OF GENE
EXPRESSION
22
2
22
7
23
2
20
9
20
0
22
6
22
3
40
3
21
6
20
6
20
7
22
1
20
3
23
1
22
9
21
7
40
9 2
30 21
5
40
6
40
0
40
1 21
0
40
8
40
7
0.
00
0
0.
00
5
0.
01
0
0.
01
5
0.
02
0
Cluster Dendrogram
hclust (*, "complete")
Dist(t(x0), method = "pearson")
H
ei
gh
t
Figure 5.13. Sample subgroups identiﬁed based on miRNA signatures
by following adaptive gene shaving
statistically signiﬁcant associations of identiﬁed sample subgroups to survival
characteristics. Further testing of the method on a large dataset consisting
of heterogeneous samples may yield better and statistically signiﬁcant asso-
ciations to the survival or other clinical characteristics.
Part II
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Chapter 6
MicroRNAs in tamoxifen
resistance
6.1 Prelude
The aim of the project presented as a manuscript “Integrative analysis of
miRNA and gene expression reveals regulatory networks in tamoxifen resis-
tance” was to perform an exploratory analysis of miRNA transcriptome in
a cell line model composed of tamoxifen sensitive MCF7 and three MCF7-
derived, tamoxifen resistant cell lines. Several studies in the area of tamoxifen
resistance have focused on a limited number of miRNAs [199, 132, 121]. This
study, therefore was planned to gain global insights into the tamoxifen
resistance conferred by miRNAs. However, to better understand the conse-
quences of miRNA expression, a gene expression dataset, generated using the
same RNA, was obtained and investigated in relation to miRNA expression
proﬁles.
This project was a collaboration with the Sino Danish breast cancer
research center, University of Copenhagen, Denmark. miRNA qPCR proﬁl-
ing was performed at Copenhagen University. Gene expression dataset was
obtained from Daniel Elias from his unpublished work. I was solely involved
in the bioinformatics analysis of data.
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Abstract
Tamoxifen is a commonly used anti-estrogen treatment for patients with
ER-positive breast cancer. Despite its eﬀectiveness, more than 30% of the
patients receiving this treatment acquire resistance to the drug. Unfor-
tunately, the underlying molecular mechanisms of drug-resistance are still
unknown.Here we study tamoxifen resistance through a systematic corre-
lation analysis of the miRNA and mRNA expression proﬁles and identify
miRNA-mediated regulation in a cell line model composed of an ER-sensitive
parental MCF-7/S0.5 and three derived tamoxifen resistant breast cancer
cell lines. We observed a signiﬁcant diﬀerential expression of a number of
miRNAs in drug resistant cell lines, suggesting their role in the develop-
ment of drug resistance. Genes regulated by these diﬀerentially regulated
miRNAs suggest that multiple mechanisms of miRNA-mediated tamoxifen
resistance exist, encompassing various receptors signaling pathways, aurora
B kinase signaling and FOXM1 transcription factor (TF) activities. Further,
our analysis identiﬁes evidences for miRNA-mediated regulation on ESR1,
6.2. MANUSCRIPT 53
PGR1, FOXM1 and 14-3-3 family genes. With the integration of such in-
ferred miRNA-target relationships and existing knowledge on TF-mediated
regulation of miRNAs and protein coding genes, we provide hints toward
FOXM1-mediated regulation of miR-135a, in the view of tamoxifen resis-
tance.
Introduction
Tamoxifen is widely used as adjuvant therapy for ER-positive breast cancer
in both pre- and post menopausal women. Tamoxifen has been shown highly
eﬀective in 26% reduction in mortality after 10 years of treatment [45] as
well as in reducing the incidence of breast cancer in patients with high risk
of developing the disease. However, almost all patients in metastatic disease
and more than 35% of the patients receiving tamoxifen as an adjuvant
therapy undergo relapse [151].
Ideally, during the initial years of the treatment, tamoxifen acts by dis-
rupting the activity of estrogen by forming a bond with ER-alpha, thereby
preventing the binding of ER-alpha to estrogen receptor. Previous studies
have shown a loss of ER-alpha expression in ER-positive breast cancer pa-
tients treated with tamoxifen [151],[122]. While the cause of such altered
expression of ER-alpha might be linked to epigenetic changes such as, hy-
permethylation of CpG islands in 5‘-regulatory regions of ER-alpha, other
genetic events that aﬀect expression of ER-alpha also exist [65]. Various
attempts have been made to characterize tamoxifen resistance via altered
expression of ER-beta, co-activators and co-repressors of ER-alpha, IGF1,
IGF1R, IGFBP3 and various other genes [151, 139, 90, 127, 126]. However,
events leading to such regulation of gene expression have not yet been com-
pletely understood.
MicroRNAs (miRNAs) are small, approximately 21 nucleotide long,
non-coding genes that regulate gene expression at the post-transcriptional
level. In mammals, more than 60% of protein-coding genes undergo post-
transcriptional regulation in the form of degradation or translation inhibition
through miRNAs. Due to their potential in regulation of tumor suppressor
or tumor promoting genes, miRNAs have recently garnered attention. The
let-7 family of miRNAs have tumor suppressive eﬀects because they target
oncogenes via post-transcriptional regulation; whereas miR-155, miR-17-5p,
miR-21 are known for their oncogenic roles in tumors [97, 145, 70]. In cancer
cells, drug-induced aberrant expression of miRNA may change drug sensi-
tivity by modulating gene expression of their target genes. Gene regulation
by miRNAs often results in activation or dysregulation of various pathways
that might be crucial for development of drug resistance or restoration
of drug sensitivity. MiR-214, miR-200c and miR-376c are critical factors
for drug resistance in a variety of cancers [23, 194, 196, 75]. For exam-
ple, miR-221/222 regulates levels of ER-alpha, and thereby plays a critical
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role in ER-positive cancers and tamoxifen resistance [199, 132]. A recent
study also showed that miR-22 oﬀers regulation of ER-alpha expression to
an even greater extent[142]. Suppression of miR-222 and miR-181b has
been shown to restore drug sensitivity in tamoxifen resistant xenografts in
mouse due their targeting eﬀect on TIMP3 [121]. Most of these studies
addressed only a limited number of miRNAs and hence they do not provide
a global view of miRNA-mediated drug resistance. Therefore, a system-
atic study of miRNA-target relationship on a cell line model may provide us
explanations as to why certain patient groups acquired resistance to the drug.
In present study investigate miRNA-mediated gene regulation using a
tamoxifen sensitive MCF-7/S0.5 cell line and three MCF-7/S0.5-derived
tamoxifen resistant cell lines, TAMR-1 (TamR1), TAMR-4 (TamR4) and
TAM-R-8 (TamR8). Since it is known that miRNA target predictions often
suﬀer from high number of false-positives, we performed an integrative
inverse-correlation analysis of miRNAs and gene expression proﬁles to dis-
tinguish genuine or functional miRNA-target relationships from miRNA
target predictions. The results provide interesting insights into aﬀected
biological processes during the drug resistance. Further, using a systems
biology approach of integrating various levels of gene regulation, we pro-
vide mechanistic hypotheses regarding transcription factor (TF) mediated
miRNA regulation and its impact on drug resistance.
Materials and Methods
Cell lines
The human breast cancer cell line MCF-7 was originally received from The
Breast Cancer Task Force Cell Culture Bank, Mason Research Institute
(Worcester, MA). The MCF-7 cells were gradually adapted to grow in low
serum concentration and the tamoxifen sensitive subline MCF-7/S0.5 [17]
was used for establishment of tamoxifen resistant cell lines by long term
treatment with 10-6 M tamoxifen as described in [123]. Three tamoxifen
resistant cell lines TAMR-1 (TamR1), TAMR-4 (TamR4) and TAM-R-8
(TamR8) were derived from distinct colonies emerged in a culture with
tamoxifen treated MCF-7/S0.5 cells [123]. The cell lines were grown in stan-
dard phenol-red-free DMEM:F12 (1:1) medium (Gibco, 21041-025) supplied
with 1% heat-inactivated FBS (Gibco, 10270-106), 6ng/ml insulin (Sigma,
I6634) and 2.5mM glutamax (Gibco, 35050). The standard medium for the
tamoxifen resistant cell lines was supplied with 10-6M tamoxifen (Sigma,
T5648). MCF-7/S0.5 and the tamoxifen resistant cell lines were passaged
once every week and seeded out with 1x105 and 1.4x105 / T25 ﬂask, re-
spectively. The cell lines were cultured at 37C and 5% CO2 and kept at
low passage numbers throughout the experiments (<10 passages) to avoid
phenotypic changes.
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miRNA quantitative real time PCR
Total RNA from cell line cultures was extracted and puriﬁed using TRIzol
(Invitrogen supplied) and EtOH precipitated. The microRNA qPCR proﬁl-
ing was conducted by the miRCURY LNA R⃝ Universal RT microRNA PCR
system (Exiqon, Denmark) according to the manufacturer‘s instructions. In
brief, 50 ng total RNA was reversed transcribed in 40 l reactions on a Bio-
RAD S1000 Thermal Cycler (60 min at 42C followed by heat-inactivation
of the reverse transcriptase for 5 min at 95C). From the resulting cDNA
32.5 l was used for a SYBR green master mix and run in 10 l real-time
ampliﬁcation on microRNA Ready-to-use PCR, Human panel I+II, V2.R
plates (Product number 203608) on a Roche LightCycler R⃝ 480 real-time
PCR system. The applied PCR settings were: 10 min at 95C, 40 ampliﬁ-
cation cycles (95C/10 sec, 60C/1 min, ramp rate 1.6C/sec). For each cell
line three independent samples were analyzed.
Gene expression microarrays
Gene expression arrays were obtained from Elias et al [48]. The authors
proﬁle gene expression of MCF-7/S0.5, TamR1, TamR4 and TamR8 using
GeneChip R⃝ Human Genome U133 plus 2 Arrays (Aﬀymetrix) in 6, 3, 3 and
2 replicates, respectively. These arrays were proﬁled by following the RNA
preparations identical to that of the miRNA qPCR assays.
Analysis of miRNA qPCR data
Primers with more than one peak in its melting characteristics were identiﬁed
and annotated via melting curve analysis performed in R.
Expression levels (Cp values) of the housekeeping genes (miRNAs or snoR-
NAs) on the qPCR assays expressed a greater degree of variance (equivalent
to more than one Cp value) across all samples. Further, Cp values of
housekeeping genes did not span the entire range of Cp values observed
in the experiment. Therefore, we applied a signal-dependent non-linear
normalization method, similar to the one described in Workman et al in
2002 [190]. The oﬀset amounts were calculated by ﬁtting cubic-spline to
the entire dataset and thereafter added to the raw data to achieve desired
target distributions. Our normalization approach oﬀered 20% reduction in
replicate standard-error of means. As a next step, we used limma [170, 171]
from Bioconductor package to determine diﬀerential expression of genes for
following contrasts: TamR1 vs. MCF7, TamR4 vs. MCF7 and TamR8 vs.
MCF7; henceforth referred to as TAMR1, TAMR4 and TAMR8, respectively.
Analysis of microarray data
Raw data was obtained from Elias et al [48]. Our inverse correlation ana-
lysis to infer functional miRNA-target relationships is highly dependent
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Figure 6.1. Schematic workﬂow of the inverse-correlation
analysis on miRNA-mRNA expression to identify functional
miRNA-targets
on the gene expression patterns. Therefore, to reduce technical variance
as much as possible, raw intensities were reanalyzed using RMA (robust
multi-array average) [87] implemented in Bioconductor package aﬀy [62].
RMA normalization consists of three steps: background correction, quantile-
normalization at probe-level and probeset summarization using a robust
linear model ﬁt to the log-transformed normalized values. Diﬀerential ex-
pression analysis was performed using limma [170, 171] package in R for
the following contrasts: TamR1 vs MCF7, TamR4 vs MCF7 and TamR8 vs
MCF7; henceforth referred to as TAMR1, TAMR4 and TAMR8, respectively.
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Integration of miRNA-mRNA expression data
An unbiased set of miRNA targets was compiled by taking a union of predic-
tions from the following target predictor tools: miRanda, miRDB, miRWalk,
PICTAR5, RNA22 and Targetscan [112, 43, 187, 73, 111, 89, 136]. An inte-
grative inverse-correlation analysis of miRNAs and gene expression proﬁles
was performed to separate genuine or functional miRNA-target relationships
from potentially noisy target predictions. We hypothesized that the observed
diﬀerential expression of mRNAs is due to the changes in expression of their
regulating miRNAs; and that the relative extent of changes in expression of
miRNA targets is higher than that of the non-targets for a given miRNA.
Due to the diﬀerences in the sample sizes of relevant cell-lines in miRNA
and mRNA expression datasets, normalized expression levels of each gene
and Cp values for every miRNA were summarized to one value per cell line
by taking an average within the relevant cell line replicate set. Since levels of
functional miRNAs are expected to be inversely proportional to their mRNA
targets and Cp values from qPCR are inversely proportional to expression
levels, a series of tests for positive correlations between miRNA and mRNA
pairs over the four resistant cell lines were performed (Figure 6.1). Such cor-
relation analysis was performed only for 191 miRNAs that were signiﬁcantly
diﬀerentially expressed (miRNA logFC0.7 and adjusted p-value<0.05)
in any of the three tamoxifen resistance cell lines. miRNA-mRNA pairs
with high positive correlation (PCC  0.8), implicating negative correlation
between mRNA and miRNA levels, were selected for further functionality
testing. These miRNA-target pairs exhibiting miRNA-mediated regulation
at expression level are referred to as functional miRNA-targets in the re-
mainder of the manuscript.
For each resistant cell line, sets of correlated miRNA-mRNA pairs were
tested by two-sample Wilcoxon rank-sum tests. Brieﬂy, each two-sided
Wilcoxon test was performed on a set of fold-changes of functional miRNA
targets versus fold-changes of non-targeted genes. P-values of Wilcoxon
tests were corrected for multiple testing errors via the Benjamini Hochberg
method [7]. If the target mRNAs had lower ranks than the background list
of mRNAs, then log10 of Wilcoxon rank sum test p-values were negated.
Results
The miRNA expression proﬁles of three tamoxifen-resistant cell lines
(TamR1, TamR4 and TamR8) and the parental ER-positive tamoxifen-
sensitive cell line (MCF7/S0.5) were analyzed for diﬀerential expres-
sion. A number of miRNAs were signiﬁcantly altered during tamoxifen-
resistance, and were in common for all three tamoxifen resistant cell lines vs
MCF7/S0.5 reftab:summary. In addition, a large number of miRNAs were
found to exhibit altered expression in one or more of the resistant cell lines.
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Table 6.1. Summary of signiﬁcantly diﬀerentially expressed
miRNAs and mRNAs. The numbers in the table refer to the
diﬀerentially expressed miRNAs and mRNAs
miR,
mRNA
change
Cell
line
miRNAs miRNAs
w corr.
targets
mRNAs miR-
reg.
mRNAs
% mRNAs
under
miR-reg.
Odds
ratio
Up,Down
TAMR1 40 28 67 44 66 1.25
TAMR4 51 30 231 137 59 1.23
TAMR8 47 33 22 11 50 0.76
Down, Up
TAMR1 29 26 204 132 65 2.31
TAMR4 52 38 205 145 71 1.23
TAMR8 48 31 125 79 63 1.57
Supplementary table 6.2 lists signiﬁcantly altered miRNAs in each of the
TAMR-contrast relative to MCF7.
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Figure 6.2. Extent of agreement in terms of miRNAs with
altered expression in tamoxifen resistant cell lines. Overlap
sizes represent agreement of induced and/or suppressed miR-
NAs during tamoxifen resistance. The circle sizes correspond
to the total number of miRNAs in each set.
Three resistant cell lines were compared for their agreement in terms of
their sets of miRNAs with altered expression. As seen in Figure 6.2, TAMR1
and TAMR4 have 13 repressed miRNAs in common, including oncomiR
miR-95; whereas TAMR1 and TAMR8 shared 16 repressed miRNAs, includ-
ing, miR-182, miR-218, miR-23b, miR-24-1, miR-611, miR-651, miR-519e
and miR-522; while TAMR4 and TAMR8 shared 19 down-regulated miR-
NAs such as miR-341-3p/5p, miR-96, miR-101, miR-29b-1, miR-183 and
miR-143. In terms of miRNAs exhibiting higher expression in tamoxifen
resistant vs. MCF-7/S0.5 cells, TamR1 and TamR4 shared 22 miRNAs,
whereas TamR1 and TamR4 share 21 miRNAs. Among these commonly
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up-regulated miRNAs were tumor suppressors miR-181b, onco-miR miR-210
and a known ER-alpha regulator miR-18a [23].
Table 6.2. miRNAs with altered expression proﬁles in all
tamoxifen-resistant cell lines compared to MCF-7/S0.5 (adjusted
p-value < 0.05).
miRNA LFC in cell line
Cell line TamR1 TamR4 TamR8
miR-218 -2.92 -1.56 3.12
miR-135a -2.84 -6.16 -4.74
miR-652 -1.99 -1.17 -1.64
miR-135b -1.89 -2.16 -2.33
miR-95 -1.82 -2.45 -1.19
miR-1248 -1.68 -1.61 -1.01
miR-101 -1.02 -3.05 -1.37
miR-152 1.29 1.4 1.49
miR-517c 2.06 1.66 1.06
miR-551b 2.09 5.79 3.51
miR-203 2.2 1.34 1.12
miR-519a 2.23 1.69 1.2
miR-516a-5p 3.47 2.87 2.46
Global analysis of miRNA-target relationships
Using our inverse-correlation analysis on miRNA-mRNA expression values,
we derived miRNA-target pairs that, in addition to being predicted targets,
also showed evidence of direct miRNA-regulation through anti-correlated
expression signatures. Figure 6.2 eluciates the possible miRNA regulation
event for a subset of miRNAs that were consistently up or down regulated in
all tamoxifen resistant cell (Fig. 6.2 a). The ﬁrst panel of the heatmap refers
to the log-ratios of miRNA expression in all three TamR vs. MCF-7/S0.5
comparisons. Through the inverse-correlation analysis, we obtained a set of
predicted targets of miRNAs that exhibited signiﬁcant negative associations
with their corresponding miRNA regulators in terms of their expression
proﬁles. Panel II and III in the heatmap represent the extent of miRNA-
regulation on such the functional targets. Direction of the fold-change for a
majority of the functional miRNA targets was coherent with respect to their
miRNA-regulators. Figure 6.2c shows a cumulative distribution function
applied on the log-ratios of genes. Functional targets of miR-135b (and miR-
516a-5p) were more up (and down) regulated compared to the non-targets
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as seen by signiﬁcant p-values of Wilcoxon rank sum test. P-values of the
Wilcoxon rank sum test were log10-transformed and assigned a sign based
on direction of fold-change of target genes (panel III in Figure 6.2 b).
Next, we derived statistics to demonstrate the extent and signiﬁcance
of miRNA-regulated diﬀerentially expressed genes. Direction of change of
expression for about 55% of the signiﬁcantly diﬀerentially expressed genes
(absolute log2-fold-changes  0.7, adjusted p-values  0.05) was coherent
with the direction of fold-changes of their miRNA regulators.
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Figure 6.3. MicroRNAs with signiﬁcant diﬀerential expres-
sion and expression of their functional targets. (a) Venn Di-
agram, number of diﬀerentially expressed in each resistant
cell-line relative to MCF7. (b) Panel I of the heatmap shows
miRNA log-fold changes. These miRNAs were signiﬁcantly
diﬀerentially expressed (absolute log2 fold-change  0.7 and
adjusted p-value < 0.05). Panel II shows (log2) ratio of counts
of up- and down-regulated targets for each miRNA. (c) Signed
log10 p-value of Wilcoxon rank-sum test.
We were particularly interested in the functions of genes under direct
miRNA-mediated regulation obtained though our inverse-correlation analy-
sis. Using genes under direct miRNA-regulation we were able to elucidate
various biological modules aﬀected by miRNA-mediated gene regulation.
Such genes in TamR1 and TamR4 cell lines showed a strong enrichment
(FDR < 0.05 for test of over-representation) for glypican pathway, IGF1
pathway, PDGFR-beta signaling, IFN-gamma pathway, plasma membrane
estrogen receptor signaling, TGF-beta signaling, nuclear and cytoplasmic
SMAD2/3, BMP signaling and class I PI3K signaling events. TamR8, despite
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of a milder response in terms of diﬀerential expression, showed quite good
agreement with signaling events in other cell lines via a smaller sized geneset.
miRNA-regulated genes exhibiting diﬀerential expression in each of
the tamoxifen resistant cell lines were investigated for their potential in
elucidating molecular mechanism devised through miRNA-mediated post-
transcriptional regulation. miRNAs in TamR1 were speciﬁcally targeting
genes characterized for pathways in cancer (FDR < 0.05) and TGF-beta
signaling (FDR < 0.05), MAPK signaling, wnt-signaling, EphrinB-EPHB
and ECM-receptor signaling pathways. MicroRNAs in TamR4 seemed to
target genes associated with signaling by Aurora kinases (FDR < 0.05),
FOXM1 transcription factor network (FDR < 0.05), and cell cycle M Phase
and G2/M transition (FDR < 0.05), Glypican pathway, FOXA transcription
factor network, PDGFR-beta signaling, Kit receptor, exon guidance and
PDGF signaling pathway. Although being not signiﬁcant, association to
functional categories for miRNA-regulated genes in TamR8 included IFN-
gamma pathway, Jak-STAT signaling, plasma membrane estrogen receptor
signaling and neurotrophin signaling pathways.
MicroRNA-mediated regulation of ER-alpha and PGR expression
We further examined the involvement of miRNAs on the key gene of ER-
positive breast cancers, ESR1 and PGR. Our integrated analysis identiﬁed
the following miRNAs as direct modulators of ER-alpha expression: miR-
199a-3p, miR-582-5p, miR-519a, miR-519b-3p, miR-521, miR-522, miR-550,
miR-519e, miR-220b, miR-22, miR-362-5p and miR-203. Such combinatorial
regulation of ER-alpha expression is strongly evident in TamR1 cell lines,
where all of the listed miRNA regulators were signiﬁcantly up regulated,
while TamR4 and TamR8 displayed the same pattern albeit to a lesser
extent( Figure 6.4). Figure 6.4a-c depict all signiﬁcantly changing miRNAs
that target ESR1 and PGR, identiﬁed by inverse-correlation. Although
both combinations, up and down regulated miRNAs were found, a clear and
signiﬁcant bias was observed for coherent changes between miRNA and their
diﬀerentially expressed targets.
Gene regulation events upstream and downstream of FOXM1 in
TamR4
FOXM1 appeared to be under a combinatorial targeting by number of
highly expressed miRNAs as shown in Figure 6.4d. Repression of FOXM1
also correlated with the repression of its downstream targets in TamR4 but
not in TamR1 or TamR8. In addition to regulating protein-coding genes,
FOXM1 has also been found to regulate transcription of miR-135a [67].
Down-regulation of miR-135 is consistent with the up-regulation of its tar-
gets, EPHA4/7 in TamR4.
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Figure 6.4. MicroRNA-mediated gene regulation inferred
from integration of diﬀerentially expressed miRNAs and their
diﬀerentially expressed mRNA targets. Functional regulation
of estrogen receptor alpha and progesterone receptor due to
diﬀerentially expressed miRNAs in TamR1 (a), TamR4 (b) and
TamR8 (c) relative to MCF-7. Evidence for FOXM1 down-
regulation by number of miRNAs in TamRX is shown in D.
Suppressed levels of FOXM1 are positively correlated with its
transcriptional targets for cell cycle regulation. FOXM1 acts
as a regulator on promoters of miR-135a, let-7f, miR-365 (d),
YWHAG and YWHAZ are under direct regulation via miR-
NAs in TamR8 (e). Color of the node corresponds to the fold-
changes observed in corresponding contrasts, whereas size of
nodes is directly related to the signiﬁcance of such diﬀerential
expression (adjusted p-values).
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Loss of miRNA regulation for YWHAG and YWHAZ
Expression of 14-3-3 family member, YWHAZ and YWHAG, were induced
in TamR8 but not in TamR1/4. These genes appeared to be under direct
regulation by a relatively small number of miRNAs, as seen in Figure 6.4e.
miR-96, miR-942, miR-378, miR-196a, miR-106b, miR-577, miR-491-5p
showed signiﬁcant down regulation in anti-correlation with YWHAG and
YWHAZ in TamR8 (adjusted p-value  0.05).
Discussion
Tamoxifen resistance is a major clinical problem in treatment of ER-positive
breast cancer, leading to recurrence of the disease in approximately 30% of the
patients. In this study we characterized tamoxifen resistance by an extensive
analysis of miRNA-mRNA expression proﬁles in 3 tamoxifen resistant cell
lines and its parental MCF-7/S0.5 cell line. miRNAs with signiﬁcantly altered
expression proﬁles in resistant cell lines compared to MCF-7, suggests their
role in drug resistance.
Based on our integrated analysis of miRNA and mRNA expression
proﬁles, we obtained a number of functional miRNA-target relationships.
Protein-coding genes often are under a direct, combinatorial regulation via
multiple miRNAs, exerting a coordinate action. Such combinatorial regula-
tory eﬀects have been described for various genes [195, 99, 84]. A table of
genes associated with signaling pathway of tamoxifen resistance is listed with
their miRNA regulators in Suppl. Table 6.2. Our analysis of miRNA-target
relationships explained the extent of gene regulation under the inﬂuence of
direct miRNA-mediated post-transcriptional regulation. Direction of altered
expression for more than 50% of the signiﬁcantly diﬀerentially expressed
genes was coherent with the expression levels of their miRNA regulators. A
functional enrichment analysis on miRNA-regulated genes showed their as-
sociations with many signaling pathways previously linked with tamoxifen
resistance. Therefore, the miRNA-target relationships inferred by this study
might be highly relevant to the acquired tamoxifen resistance.
A number of known regulatory relationships that were not identiﬁed
were found to be in agreement upon further inspection. Lykkesfeldt et
al. showed that a loss of expression of estrogen receptor often leads to
tamoxifen resistance [122]. For example miR-22 regulates ER-alpha by
direct post-transcriptional regulation [65] and although not observed in the
inverse correlation analysis, expression of miR-22 and ESR1 was found to
be anti-correlated with smaller fold-changes. MiR-221 and miR-222, regu-
lators of ER-alpha expression were studied under both tamoxifen sensitive
(MCF7) and tamoxifen resistant cell lines suggest that over expression of
these miRNAs is correlated to the drug resistance [134]. Our data supported
this hypothesis only partially. MiR-221 expression was slightly induced in
TamR1 and TamR4 but not in TamR8, whereas expression of miR-222 was
suppressed speciﬁcally in TamR4. Given that miR-221/222 share identical
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seed sequence and are located less than 1kb apart on chromosome X, an
upstream regulation is more likely to modulate miR-222 levels than an
epigenetic eﬀect.
Our systematic approach of integrating various evidences of gene regula-
tion with miRNA-target expression proﬁles revealed a small linear pathway
in TamR4. Forkhead box protein, FOXM1, also a known regulator of estro-
gen receptor alpha in breast cancer cells [120], is associated with positive
regulation of its direct transcriptional targets CCNB1, CCNA2, PLK1, au-
rora B kinase, Cdc25B phosphatase and CENPF. FOXM1 is a modulator of
G1/S and G2/M transition, cell cycle, DNA replication, chromosomal segre-
gation and stability during mitosis. FOXM1 has been recently characterized
for binding to the promoter of miR-135a and exerting a positive regulatory
eﬀect on miR-135a [120]. Among all resistant cell lines, miR-135a levels
are most down regulated in TamR4, suggesting an additional regulation of
miR-135a transcription through FOXM1 (Figure 6.4),especially in TamR4.
MiR-135 modulates expression of several genes in TamR4, among which
EPHA4 and EPHA7 are speciﬁcally up regulated in TamR4 but not in other
resistant cell lines. Due to the functional interactions of these genes with
FYN, YES1, LYN, etc, Ephrins are beeing seen as therapeutic targets in
cancer due to their crucial role in development and progression of cancer,
metastasis as well as in the inhibition of tumorigenicity [16]. Also, high
expression levels of EphA4 and EphA7 have recently been associated with
poor overall survival in breast cancer [44]. Taken together, FOXM1 desreg-
ulation, followed by a loss of function of miR-135a and a loss of regulation
of Eph receptors may play role in development of drug resistance in TamR4.
An experimental validation of protein expression of FOXM1, ephrins as well
as a silencing experiment for miR-135a is required to conﬁrm this hypothesis.
The 14-3-3 (YWHA) proteins are highly conserved proteins that have
been implicated in regulating cell cycle, apoptosis and recently also in cancers.
14-3-3 (YWHAG) has been shown to exert its oncogenic eﬀects through
activation of MAPK and PIK pathways [144]. 14-3-3 or YWHAGZ is often
up regulated in patients receiving tamoxifen adjuvant therapy. In addition,
over expression of this gene is related to poor patient survival [8, 58, 59].
In our dataset, both of these genes were up regulated in TamR8 but not in
TamR1/4. miR-96, miR-942, miR-378, miR-196a, miR-106b, miR-577 and
miR-491-5p showed signiﬁcant down regulation in TamR8 (adjusted p-value
leq 0.05), expressing a direct eﬀect of miRNA-mediated regulation. Berga-
maschi et al [9], recently showed that tamoxifen bears a suppressive role on
expression of miR-451 in on TamR cell lines by inducing loss-of-regulation
of YWHAZ due to down-regulation of miR-451, its miRNA regulator. We,
however, did not ﬁnd a signiﬁcant over expression of miR-451 in our dataset.
This is likely due to the fact that miR-451 was ﬂagged a as poor quality
assay in our dataset due to multiple peaks observed in the melting curve
characteristics of its qPCR primer. Nevertheless, this small yet critical event
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of miRNA-mediated regulation of 14-3-3 family member genes might be of
high clinical relevance after further experimental validations.
miRNAs with altered expression in tamoxifen resistant cell lines showed
an agreement with the ﬁndings of earlier studies within the area of tamoxifen
resistance. Lyng et al [125] performed a study on a large cohort of 152
primary breast cancer patients treated with tamoxifen, grouped by their
recurrence status and various other clinical characteristics. We tried to
investigate whether the diﬀerences in the miRNA expression signatures in
the resistant cell lines showed any agreement with the diﬀerences in the
expression patterns observed between recurrent and nonrecurrent groups.
Over-expression of miR-205 and miR-363 in TamR8 corresponds to over
expression seen in the recurrent group in test set # 1 that consisted of
samples of recurrent type and characterized by a high levels of tumor in-
ﬁltrated lymphnodes (8.6, on an average). Signiﬁcant down-regulation of
miR-29b in TamR4 relates to a dysregulation of this miRNA in testset # 3,
characterized by 3-5 years of average tamoxifen therapy. Further, miR-190b
and miR-135a, down-regulated in all tamoxifen resistant cell lines were also
the most signiﬁcantly dysregulated miRNAs between recurrent and non-
recurrent groups in the discovery set that consisted of a patient-group with
an average 2 years of exposure to tamoxifen therapy, and a positive lymph
nodes status. Therefore, a systematic comparison of the ﬁndings achieved
through the use of cell line model to clinical samples would help explain the
mechanisms of resistance in vivo .
Next, we assessed whether the observed miRNA expression changes were
in agreement with the already known tamoxifen resistance related miRNAs.
Over expression of miR-181b expression has previously been studied with
a view of tamoxifen resistance [121]. In our dataset, miR-181b was con-
sistently up regulated in all resistant cell lines, suggesting its contribution
to a common machinery to confer drug resistance. A closer look at the
functional targets of miR-181b provided us with set of key regulators of
breast cancer and drug resistance related genes with signiﬁcant down regula-
tion: for example, HEY1, CA2, PIK3R1, LYN, ESR1, JUN, STAT1, MYB,
BCL2, CYCS, BAMBI, CTGF, and SOX9. Another miRNA consistently
down regulated in all resistant cell lines was miR-342. Down regulation of
miR-342 has been linked with tamoxifen resistance by Cittelly et al [32].
We identiﬁed 14 functional targets of miR-342-3p and -5p, some of which
were FYN, TGFBR1, COL4A6, CDKN1A, and Ephrins EPHA4/7 (Suppl.
Fig 6.5). Taken together, targets of previously characterized miR-181b and
miR-342 were highly relevant to anti-estrogen resistance and therefore, could
be investigated for their potential in restoration of drug sensitivity.
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Conclusion
In conclusion, our systematic approach of inferring miRNA-target rela-
tionships elucidated important and detailed lines of events contributing to
the development of drug resistance. Several miRNA-target relationships
were identiﬁed, many of which showed signiﬁcant association to various
signaling events known to be associated with the development of tamoxifen
resistance. Combinatorial miRNA targeting as well as post-transcriptional
modiﬁcations to the upstream promoters of miRNAs and/or their targets.
Therefore, an experimental validations of some of our ﬁndings is necessary
and is in progress. Nonetheless, this study provides hints toward such events
occurring during tamoxifen resistance and is likely to correspond with the
miRNA-mediated gene regulation in patient material of speciﬁc characteris-
tics.
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Supplementary ﬁles
Table 6.3. List of signiﬁcantly diﬀerentially expressed miR-
NAs. miRNAs with signiﬁcantly altered expression proﬁles in
tamoxifen resistant cell lines relative to MCF7 cell line. (Ab-
solute log-ratio of expression 1 AND adjusted p-value  0.05)
Contrast (relative
to MCF7 cell line)
List of diﬀerentially expressed miRNAs
TAMR1 hsa-miR-101, hsa-miR-1203, hsa-miR-1248, hsa-miR-
130b, hsa-miR-132, hsa-miR-135a, hsa-miR-135b, hsa-
miR-142-3p, hsa-miR-152, hsa-miR-153, hsa-miR-182,
hsa-miR-1913, hsa-miR-196a, hsa-miR-196b, hsa-miR-
1979, hsa-miR-199b-5p, hsa-miR-200a, hsa-miR-203,
hsa-miR-212, hsa-miR-215, hsa-miR-218, hsa-miR-22,
hsa-miR-220b, hsa-miR-23b, hsa-miR-24-1, hsa-miR-
339-5p, hsa-miR-33b, hsa-miR-345, hsa-miR-34b, hsa-
miR-362-5p, hsa-miR-516a-5p, hsa-miR-517b, hsa-miR-
517c, hsa-miR-519a, hsa-miR-519b-3p, hsa-miR-519e,
hsa-miR-519e, hsa-miR-522, hsa-miR-551b, hsa-miR-
577, hsa-miR-582-5p, hsa-miR-593, hsa-miR-611, hsa-
miR-649, hsa-miR-652, hsa-miR-943, hsa-miR-95
TAMR4 hsa-miR-1, hsa-miR-101„ hsa-miR-101, hsa-miR-1201,
hsa-miR-1248, hsa-miR-130b, hsa-miR-135a, hsa-miR-
135b, hsa-miR-138, hsa-miR-143, hsa-miR-149, hsa-miR-
149, hsa-miR-152, hsa-miR-153, hsa-miR-181b, hsa-
miR-181c, hsa-miR-183, hsa-miR-18a, hsa-miR-18b, hsa-
miR-190, hsa-miR-1908, hsa-miR-190b, hsa-miR-191,
hsa-miR-192, hsa-miR-193a-3p, hsa-miR-1979, hsa-miR-
200a, hsa-miR-203, hsa-miR-21, hsa-miR-210, hsa-miR-
2113, hsa-miR-218, hsa-miR-26a-2, hsa-miR-29b, hsa-
miR-30a, hsa-miR-330-3p, hsa-miR-337-3p, hsa-miR-339-
5p, hsa-miR-33a, hsa-miR-33b, hsa-miR-33b, hsa-miR-
342-3p, hsa-miR-342-5p, hsa-miR-345, hsa-miR-424, hsa-
miR-424, hsa-miR-499-5p, hsa-miR-503, hsa-miR-516a-
5p, hsa-miR-517c, hsa-miR-519a, hsa-miR-519e, hsa-miR-
520d-3p, hsa-miR-522, hsa-miR-524-5p, hsa-miR-548k,
hsa-miR-551b, hsa-miR-580, hsa-miR-600, hsa-miR-628-
5p, hsa-miR-629, hsa-miR-652, hsa-miR-7, hsa-miR-708,
hsa-miR-720, hsa-miR-941, hsa-miR-95, hsa-miR-96
TAMR8 hsa-let-7i, hsa-miR-101, hsa-miR-101, hsa-miR-106b,
hsa-miR-1201, hsa-miR-1203, hsa-miR-1248, hsa-miR-
129, hsa-miR-135a, hsa-miR-135b, hsa-miR-142-3p, hsa-
miR-143, hsa-miR-152, hsa-miR-182, hsa-miR-183, hsa-
miR-1908, hsa-miR-190b, hsa-miR-192, hsa-miR-194,
hsa-miR-196a, hsa-miR-203, hsa-miR-205, hsa-miR-20b,
hsa-miR-210, hsa-miR-215, hsa-miR-218, hsa-miR-22,
hsa-miR-23b, hsa-miR-24-1, hsa-miR-24-2, hsa-miR-
30a, hsa-miR-328, hsa-miR-340, hsa-miR-342-5p, hsa-
miR-363, hsa-miR-375, hsa-miR-378, hsa-miR-378, hsa-
miR-449a, hsa-miR-455-3p, hsa-miR-455-5p, hsa-miR-
491-5p, hsa-miR-503, hsa-miR-516a-5p, hsa-miR-517c,
hsa-miR-519a, hsa-miR-519e, hsa-miR-551b, hsa-miR-
574-3p, hsa-miR-577, hsa-miR-582-5p, hsa-miR-590-5p,
hsa-miR-611, hsa-miR-628-3p, hsa-miR-652, hsa-miR-
720, hsa-miR-877, hsa-miR-93, hsa-miR-942, hsa-miR-
95, hsa-miR-96
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Table 6.4: Functional miRNA-target relationship inferred by
inverse-correlation analysis
Gene Regulating miRNAs
MYCN hsa-miR-30a, hsa-miR-34b, hsa-miR-449a
NFKB1 hsa-miR-548d-5p, hsa-miR-577
YWHAG hsa-miR-1183, hsa-miR-216a, hsa-miR-378, hsa-miR-510,
hsa-miR-548d-5p, hsa-miR-877, hsa-miR-942, hsa-miR-
96
YWHAZ hsa-miR-106b, hsa-miR-196a, hsa-miR-491-5p, hsa-miR-
548d-5p, hsa-miR-577
FOXM1 hsa-miR-149, hsa-miR-149, hsa-miR-1914, hsa-miR-
602, hsa-miR-7
BMP7 hsa-miR-199a-5p
CD59 hsa-miR-1201, hsa-miR-1248, hsa-miR-135b, hsa-miR-
190b, hsa-miR-196a, hsa-miR-23b, hsa-miR-24-1, hsa-
miR-378, hsa-miR-429, hsa-miR-485-3p, hsa-miR-577,
hsa-miR-593, hsa-miR-616, hsa-miR-627
CDKN2B hsa-miR-1244, hsa-miR-155, hsa-miR-196a, hsa-miR-23b,
hsa-miR-429, hsa-miR-519e, hsa-miR-577, hsa-miR-93
CLU hsa-miR-1913, hsa-miR-378
COL5A1 hsa-miR-199a-5p, hsa-miR-218, hsa-miR-517b, hsa-miR-
649, hsa-miR-766
CPE hsa-miR-335, hsa-miR-33b, hsa-miR-616
DUSP6 hsa-miR-1248, hsa-miR-33b, hsa-miR-649
EFNB2 hsa-miR-153, hsa-miR-199a-5p, hsa-miR-218, hsa-miR-
33b, hsa-miR-34b, hsa-miR-548i, hsa-miR-767-5p
EPAS1 hsa-miR-196a, hsa-miR-23b, hsa-miR-577
FZD7 hsa-miR-149, hsa-miR-34b, hsa-miR-593, hsa-miR-766
FZD8 hsa-miR-517b, hsa-miR-943
IRF6 hsa-miR-1248, hsa-miR-23b
ITPR1 hsa-miR-429, hsa-miR-577
LYN hsa-miR-1248, hsa-miR-147b, hsa-miR-199a-5p, hsa-miR-
33b, hsa-miR-513a-3p
MAGED1 hsa-miR-513a-3p
MAP1B hsa-miR-1248, hsa-miR-135b, hsa-miR-153, hsa-miR-
23b, hsa-miR-33b, hsa-miR-593, hsa-miR-616, hsa-miR-
649, hsa-miR-943
MYO1B hsa-miR-155, hsa-miR-378, hsa-miR-548d-5p, hsa-miR-
611
NOG hsa-miR-429, hsa-miR-593
NRP1 hsa-miR-1248, hsa-miR-153, hsa-miR-23b, hsa-miR-485-
3p, hsa-miR-604
PCDH8 hsa-miR-101, hsa-miR-153
PLAU hsa-miR-23b, hsa-miR-593
PRICKLE2 hsa-miR-1248, hsa-miR-135b, hsa-miR-153, hsa-miR-
182, hsa-miR-196a, hsa-miR-23b, hsa-miR-33b, hsa-
miR-593, hsa-miR-616, hsa-miR-627, hsa-miR-649
PRKCA hsa-miR-1248, hsa-miR-135b, hsa-miR-135b, hsa-miR-
147b, hsa-miR-182, hsa-miR-183, hsa-miR-196a, hsa-
miR-23b, hsa-miR-30a, hsa-miR-485-3p, hsa-miR-548k,
hsa-miR-604, hsa-miR-616, hsa-miR-95
SDC2 hsa-miR-101, hsa-miR-1183, hsa-miR-135b, hsa-miR-
182, hsa-miR-23b, hsa-miR-24-1, hsa-miR-485-3p, hsa-
miR-577, hsa-miR-627
SH3BGRL hsa-miR-135b, hsa-miR-196a, hsa-miR-485-3p, hsa-miR-
649
TCF7L1 hsa-miR-218, hsa-miR-455-3p, hsa-miR-517
TGFB2 hsa-miR-593
THBS1 hsa-miR-1913
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ARHGEF6 hsa-miR-1253, hsa-miR-130b, hsa-miR-144, hsa-miR-
199b-5p, hsa-miR-220b, hsa-miR-33a, hsa-miR-522, hsa-
miR-582-5p, hsa-miR-589
CACNA1D hsa-miR-142-3p, hsa-miR-144, hsa-miR-199b-5p, hsa-
miR-519e, hsa-miR-522, hsa-miR-582-5p
CAP2 hsa-miR-132, hsa-miR-203, hsa-miR-212, hsa-miR-522,
hsa-miR-582-5p
ELOVL2 hsa-miR-144, hsa-miR-152, hsa-miR-18a, hsa-miR-203,
hsa-miR-22, hsa-miR-339-5p, hsa-miR-519e, hsa-miR-
550, hsa-miR-888
ERBB4 hsa-miR-1253, hsa-miR-130b, hsa-miR-144, hsa-miR-
18a, hsa-miR-18b, hsa-miR-199b-5p, hsa-miR-203, hsa-
miR-22, hsa-miR-220b, hsa-miR-339-5p, hsa-miR-33a,
hsa-miR-345, hsa-miR-362-5p, hsa-miR-518d-5p, hsa-
miR-518e, hsa-miR-519a, hsa-miR-519b-3p, hsa-miR-
519e, hsa-miR-522, hsa-miR-524-5p, hsa-miR-525-5p,
hsa-miR-580, hsa-miR-589, hsa-miR-609
ESR1 hsa-miR-199a-3p, hsa-miR-203, hsa-miR-22, hsa-miR-
220b, hsa-miR-362-5p, hsa-miR-519a, hsa-miR-519b-3p,
hsa-miR-519e, hsa-miR-521, hsa-miR-522, hsa-miR-550,
hsa-miR-582-5p
GREB1 hsa-miR-130b, hsa-miR-152, hsa-miR-192, hsa-miR-203,
hsa-miR-20b, hsa-miR-215, hsa-miR-22, hsa-miR-220b,
hsa-miR-550, hsa-miR-582-5p
GULP1 hsa-miR-144, hsa-miR-199a-3p, hsa-miR-203, hsa-miR-
33a, hsa-miR-362-5p, hsa-miR-522, hsa-miR-582-5p
KIAA1324 hsa-miR-519e
MGP hsa-miR-152
NFKBIA hsa-miR-519a
NPY1R hsa-miR-1253, hsa-miR-132, hsa-miR-203, hsa-miR-212,
hsa-miR-522, hsa-miR-582-5p
SGK1 hsa-miR-142-3p, hsa-miR-144, hsa-miR-522, hsa-miR-
582-5p
SULF1 hsa-miR-1, hsa-miR-138, hsa-miR-196b, hsa-miR-330-3p,
hsa-miR-330-5p, hsa-miR-340, hsa-miR-34b
TM4SF1 hsa-miR-491-5p, hsa-miR-548d-5p, hsa-miR-640
ACADL hsa-miR-135a, hsa-miR-135b, hsa-miR-32, hsa-miR-424,
hsa-miR-503, hsa-miR-548k
ARMCX1 hsa-miR-424, hsa-miR-503, hsa-miR-96
ATP9A hsa-miR-1248, hsa-miR-135a, hsa-miR-135b, hsa-miR-
187, hsa-miR-190b, hsa-miR-30a, hsa-miR-33b, hsa-
miR-342-5p, hsa-miR-548k, hsa-miR-604, hsa-miR-627,
hsa-miR-649, hsa-miR-708
CAMK2B hsa-miR-138, hsa-miR-342-3p, hsa-miR-708
CD36 hsa-miR-143, hsa-miR-216a, hsa-miR-486-5p, hsa-miR-96
CPT1C hsa-miR-342-3p
CTGF hsa-miR-138, hsa-miR-181c, hsa-miR-330-3p, hsa-miR-
330-5p, hsa-miR-597, hsa-miR-708
DDX58 hsa-miR-101, hsa-miR-135a, hsa-miR-181c, hsa-miR-
193a-3p, hsa-miR-30a, hsa-miR-32, hsa-miR-330-5p,
hsa-miR-335, hsa-miR-597, hsa-miR-600, hsa-miR-708
EGR2 hsa-miR-138, hsa-miR-181c, hsa-miR-190, hsa-miR-200a,
hsa-miR-330-3p, hsa-miR-335, hsa-miR-424, hsa-miR-
548i, hsa-miR-548k, hsa-miR-708
EPHA4 hsa-miR-1201, hsa-miR-1248, hsa-miR-135a, hsa-miR-
135b, hsa-miR-181c, hsa-miR-183, hsa-miR-193a-3p,
hsa-miR-335, hsa-miR-342-3p, hsa-miR-342-5p, hsa-
miR-486-5p, hsa-miR-548k, hsa-miR-627, hsa-miR-708
FDFT1 hsa-miR-181c, hsa-miR-424, hsa-miR-548k, hsa-miR-708
FYN hsa-miR-33b, hsa-miR-342-5p
IFIT1 hsa-miR-183, hsa-miR-600
IFNB1 hsa-miR-138
IFNGR1 hsa-miR-183, hsa-miR-335
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IL15 hsa-miR-101, hsa-miR-101, hsa-miR-200a, hsa-miR-32,
hsa-miR-424
IRF9 hsa-miR-302e, hsa-miR-600, hsa-miR-627
JUP hsa-miR-342-5p, hsa-miR-424, hsa-miR-627, hsa-miR-708
OASL hsa-miR-15a, hsa-miR-183, hsa-miR-193a-3p, hsa-miR-
338-3p, hsa-miR-597, hsa-miR-708
PLCXD3 hsa-miR-153, hsa-miR-181c, hsa-miR-183, hsa-miR-190,
hsa-miR-199a-5p, hsa-miR-26a-1, hsa-miR-302e, hsa-
miR-30a, hsa-miR-330-3p, hsa-miR-335, hsa-miR-338-
3p, hsa-miR-33b, hsa-miR-342-3p, hsa-miR-499-5p, hsa-
miR-513a-3p, hsa-miR-548i, hsa-miR-548k, hsa-miR-597
PRKD1 hsa-miR-200a
PTGES hsa-miR-193a-3p, hsa-miR-330-3p
RAPGEFL1 hsa-miR-138, hsa-miR-302e, hsa-miR-337-3p, hsa-miR-
424, hsa-miR-486-5p, hsa-miR-520d-3p, hsa-miR-604,
hsa-miR-708
RPRM hsa-miR-105, hsa-miR-26a-1, hsa-miR-30a, hsa-miR-
33b, hsa-miR-424, hsa-miR-424, hsa-miR-627
STAT1 hsa-miR-101, hsa-miR-1248, hsa-miR-135a, hsa-miR-
135b, hsa-miR-181c, hsa-miR-183, hsa-miR-335, hsa-
miR-548k
TGFBR3 hsa-miR-1, hsa-miR-138, hsa-miR-181c, hsa-miR-193a-
3p, hsa-miR-200a, hsa-miR-330-3p, hsa-miR-330-5p, hsa-
miR-335, hsa-miR-338-3p, hsa-miR-342-3p, hsa-miR-
342-5p, hsa-miR-424, hsa-miR-628-5p
TLR2 hsa-miR-548k
TNFAIP3 hsa-miR-1, hsa-miR-101, hsa-miR-1201, hsa-miR-138,
hsa-miR-15a, hsa-miR-183, hsa-miR-193a-3p, hsa-miR-
200a, hsa-miR-330-5p, hsa-miR-335, hsa-miR-337-3p,
hsa-miR-424, hsa-miR-503
ADIPOR2 hsa-miR-223, hsa-miR-524-5p, hsa-miR-525-5p, hsa-miR-
629
AURKA hsa-miR-129-3p, hsa-miR-149, hsa-miR-149, hsa-miR-
629
BAMBI hsa-miR-142-5p, hsa-miR-20b, hsa-miR-888
BCL2L12 hsa-miR-7
C12orf32 hsa-miR-18a, hsa-miR-18b
CCNA2 hsa-miR-1267, hsa-miR-524-5p, hsa-miR-589
CCNB1 hsa-miR-144
CCND1 hsa-miR-149, hsa-miR-18b, hsa-miR-1914, hsa-miR-524-
5p, hsa-miR-593, hsa-miR-602
CDCA8 hsa-miR-149
CDKN1B hsa-miR-1267, hsa-miR-223, hsa-miR-33b, hsa-miR-524-
5p, hsa-miR-580
CENPA hsa-miR-524-5p, hsa-miR-629
CENPF hsa-miR-33b
CTNNAL1 hsa-miR-525-5p
CXCL12 hsa-miR-137, hsa-miR-152, hsa-miR-20b, hsa-miR-455-
5p, hsa-miR-518d-5p, hsa-miR-550, hsa-miR-609, hsa-
miR-720, hsa-miR-888
EIF4EBP1 hsa-miR-18a, hsa-miR-551b, hsa-miR-609
FOXC1 hsa-miR-149, hsa-miR-1914, hsa-miR-345, hsa-miR-
517c, hsa-miR-518d-5p, hsa-miR-518e, hsa-miR-522,
hsa-miR-524-5p, hsa-miR-609, hsa-miR-639
GAB2 hsa-miR-1267, hsa-miR-149, hsa-miR-152, hsa-miR-18a,
hsa-miR-18b, hsa-miR-1908, hsa-miR-192, hsa-miR-20b,
hsa-miR-339-5p, hsa-miR-518d-5p, hsa-miR-550, hsa-
miR-886-3p
GNB4 hsa-miR-142-5p, hsa-miR-192, hsa-miR-20b, hsa-miR-
450b-3p, hsa-miR-455-5p, hsa-miR-517, hsa-miR-518d-
5p, hsa-miR-888
IGF1R hsa-let-7i, hsa-miR-142-5p, hsa-miR-152, hsa-miR-20b,
hsa-miR-375, hsa-miR-450b-3p, hsa-miR-455-5p
6.2. MANUSCRIPT 71
IL6ST hsa-miR-223
IRS2 hsa-miR-137, hsa-miR-142-5p, hsa-miR-152, hsa-miR-
192, hsa-miR-192, hsa-miR-215, hsa-miR-375, hsa-miR-
550
KIF23 hsa-miR-191, hsa-miR-223, hsa-miR-7
NCAPD2 hsa-miR-33b, hsa-miR-519e
NCAPG hsa-miR-629
NCAPH hsa-miR-1267, hsa-miR-149, hsa-miR-593
NEK2 hsa-miR-629
PCDH7 hsa-miR-142-5p, hsa-miR-144, hsa-miR-524-5p, hsa-miR-
580
PCK2 hsa-miR-18a, hsa-miR-223, hsa-miR-550, hsa-miR-580
PPM1E hsa-miR-1256, hsa-miR-137, hsa-miR-1908, hsa-miR-205,
hsa-miR-20b, hsa-miR-888
PRKAR2B hsa-miR-1256, hsa-miR-130b, hsa-miR-137, hsa-miR-
19b-2, hsa-miR-450b-3p, hsa-miR-518d-5p, hsa-miR-
524-5p, hsa-miR-580
RAB11FIP3 hsa-miR-149, hsa-miR-941
RAB31 hsa-miR-1256, hsa-miR-130b, hsa-miR-149, hsa-miR-
152, hsa-miR-339-5p, hsa-miR-33a, hsa-miR-518d-5p,
hsa-miR-524-5p, hsa-miR-580, hsa-miR-589
RACGAP1 hsa-miR-130b, hsa-miR-149, hsa-miR-223
SMC2 hsa-miR-142-5p, hsa-miR-144, hsa-miR-223, hsa-miR-
524-5p, hsa-miR-525-5p, hsa-miR-580, hsa-miR-7
SOX3 hsa-miR-22, hsa-miR-518d-5p
SVIL hsa-miR-524-5p, hsa-miR-525-5p, hsa-miR-580, hsa-miR-
589
TFAP2C hsa-miR-1267, hsa-miR-550, hsa-miR-602
TLE1 hsa-miR-191, hsa-miR-524-5p
TSPAN5 hsa-miR-144, hsa-miR-199a-3p
CHFR hsa-miR-1913, hsa-miR-577, hsa-miR-593
CP hsa-miR-548d-5p
CROT hsa-miR-106b, hsa-miR-1183, hsa-miR-590-5p, hsa-miR-
611
IL7 hsa-miR-548d-5p
INPP4B hsa-miR-216a, hsa-miR-590-5p, hsa-miR-640
IRX2 hsa-miR-93, hsa-miR-942
LEPR hsa-miR-216a, hsa-miR-378, hsa-miR-510, hsa-miR-584,
hsa-miR-590-5p
PDCD6 hsa-miR-548d-5p, hsa-miR-590-5p
PRLR hsa-miR-106b, hsa-miR-548d-5p
TPD52 hsa-miR-135b, hsa-miR-155, hsa-miR-182, hsa-miR-
196a, hsa-miR-23b, hsa-miR-429, hsa-miR-548d-5p
BMPR1B hsa-miR-205, hsa-miR-20b, hsa-miR-218, hsa-miR-328,
hsa-miR-375, hsa-miR-554, hsa-miR-628-3p, hsa-miR-888
OSMR hsa-miR-513a-3p, hsa-miR-943
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Figure 6.5. Regulation of FYN through miR-342-5p and miR-
342-3p. Solid blue edges indicate miRNA regulation at post-
transcription level. Dotted edges represent protein-protein in-
teractions. FYN is a direct target of miR-342-5p.
Chapter 7
MicroRNAs in Disease
Progression
7.1 Prelude
The project presented as the manuscript “MicroRNA proﬁling suggest a role
for MYC and NFKB1 mediated dysregulation of microRNA expression in
the transformation of low-grade ocular MALT to diﬀuse large B-cell lym-
phoma”’ aims at characterizing the role of miRNAs in the transformation of
low-grade ocular mucosa associated lymphoid tissue lymphoma (MALT) to
a high-grade and malignant diﬀuse large B-cell lymphoma (DLBCL) using
miRNA expression proﬁling on patient samples.
MALT, although being an indolent and relatively rare disease, the mech-
anisms by which the disease transforms into the malignant lymphoma are
not very well known. A recent study with the goal of understanding such
transformation for gastric MALT to gastric DLBCL identiﬁed the signature
of dysregulated miRNAs and their interplay with MYC, an oncogene [38].
However, the molecular aspects of the transformation from ocular MALT to
ocular DLBCL have not explored in much detail due to the limited amount
of diagnostic material and also the need for frozen tissue samples. MicroR-
NAs, on the other hand can still be preserved in the formalin ﬁxed paraﬃn
embedded (FFPE) samples and very small amounts of materials are needed
for the analysis. Therefore, more than 40 patient samples of ocular MALT
and ocular DLBCL were analyzed for miRNA expression using microarrays.
This project was a collaboration with the Department of Hematology and the
Department of Pathology, Rigshospitalet, Copenhagen, Denmark. miRNA
microarrays and qPCR proﬁling was performed at Rigshospitalet.
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Abstract
Ocular adnexal lymphoma, although rare, are one of the most common type
kind of malignancies involving orbital adnexal regions of the eye. Often indo-
lent in nature, the low-grade mucosa associated lymphoid tissue lymphoma
(MALT) can transform into the malignant diﬀuse large B cell lymphomas
(DLBCLs) of eye. It is unclear, however, that which genetic events lead to
the transformation of low-grade disease to a malignant and potentially fatal
disease. We performed a global miRNA expression proﬁling of 18 MALT and
25 DLBCL clinical samples to investigate changes in the miRNA expression
associated with the disease transformation. Our data analysis revealed 40
miRNAs with altered expression proﬁles in DLBCL with respect to MALT.
Twenty-nine of the down regulated miRNAs showed enrichment for a direct
transcriptional repression by MYC, an oncoprotein. We also report a possible
loss-of-regulation of NFKB1 and its downstream miRNAs.
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Introduction
Ocular adnexal lymphoma, found in the eyelid, conjunctiva, lacrimal sac,
lacrimal gland, and orbit, is a heterogeneous group of malignancies repre-
senting 6-8% of the extranodal non-Hodgkin lymphomas (NHL) [189, 60]
and, although rare, is the most common malignancy of the orbit [168].
Mucosa-associated lymphoid tissue lymphoma (MALT), also known ex-
tranodal marginal zone lymphoma or EMZL, is the most frequent ocular
lymphoma and is indolent in nature [169]. A prolonged history of ocular
MALT (eMALT) is often followed by disease progression and transformation
toward diﬀuse large B-cell lymphoma in the orbit or adnexa (eDLBCL).
Further, it has recently been shown that during a 52 months follow-up, 4%
of the low-grade eMALT patient samples transformed to diﬀuse large B cell
lymphoma in a large cohort of OAL patients [155]. However, it is unknown
how many DLBCLs are indeed preceded by a MALT lesion, suggesting that
the numbers may be higher. The molecular aspects distinguishing ocular
MALT from ocular DLBCL have not been explored in much detail, mainly
due to the limited amount of diagnostic material and the requirement of
fresh frozen tissue for most diagnostic methods. Most previous studies of
tumor suppressor pathways in lymphoma have focused on the disruption of
the coding sequences of genes. However, it is now evident that epigenetic
alterations and aberrant expression of non-coding RNAs, such as microR-
NAs, may be equally important for disease development and transformation
to malignant forms of disease.
MicroRNAs (miRNAs) are 19-22 nucleotide long noncoding RNAs that
target complementary regions in the 3’UTR of protein encoding mRNAs and
may disrupt gene expression by either mRNA degradation or translational
inhibition. A single miRNA may inﬂuence the expression of number of pro-
tein encoding genes, therefore, even moderate changes in miRNA expression
may have great impact on tumorigenesis [37, 163]. For example, miR-16,
miR-143, miR-145 and let-7 family miRNAs have tumor suppressive eﬀects;
whereas miR-125b-1, miR-1 and miR-17-92 cluster members are linked with
tumor proliferative or oncogenic activities [49]. Dysregulation of miRNAs,
whether from genetic or epigenetic events, can lead to the loss of miRNA
regulation (loss-of-function) [160] and often disrupt the expression of protein
coding genes [6]. Recent work by Craig et al. [38] describes the interplay
between MYC, miR-34a and FOXP1 during transformation of gastric MALT
to gastric DLBCL.
In the present study we attempt to distinguish the diﬀerences in miRNA
regulation between ocular MALT and ocular DLBCL using miRNA expres-
sion proﬁling of formalin-ﬁxed paraﬃn-embedded (FFPE) specimens from
patients suﬀering from these diseases. We aimed to understand mechanisms
for low-grade eMALT to eDLBCL transformation by applying an integrative
bioinformatics approach to miRNA targeting networks and miRNA expres-
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sion proﬁles.
Material and methods
Patient samples
The study includes specimens from 25 patients with ocular DLBCL, and 18
patients with ocular MALT. All eMALTs were orbital biopsies, while the 25
DLBCLs were biopsied from the orbit (18), lacrimal gland (3), eyelid (3) and
conjunctiva (1). The FFPE specimens were retrieved from several Danish
pathological departments during year 1980 to year 2009. For histopatholog-
ical examination, all sections were stained with haematoxylin-eosin (H&E)
and analysed immunohistochemically using the following panel of antibodies:
bcl-2, bcl-6, CD3, CD5, CD10, CD20, CD23, CD 79, cyclin D-1, MUM-1
and MIB-1 (Ki-67). Two independent pathologists (ER, SH) examined and
reviewed the samples and, in agreement, reclassiﬁed the specimens according
to the World Health Organization Classiﬁcation of Tumours of Haematopoi-
etic and Lymphoid Tissues [22]. As per classiﬁcation by Hans et al. [77],
DLBCL samples were classiﬁed as of germinal cell like (GCB) or non-GCB
types.
Ethics
The study followed the tenets of the Helsinki Declaration and was approved
by the local ethics committee (Journal no. H-B-2009-054) and the Danish
Data Protection Agency (Journal no. 2009-41-3281). The authors declare
no conﬂicts of interest
RNA extraction
Total RNA was isolated from four to eight 10 µm tissue sections using the
RecoverAll, Total Nucleic Acid Isolation Kit (Applied Biosystems/Ambion,
USA) according to manufacturer guidelines. Brieﬂy, the samples were in-
cubated in Xylene at 50C to remove paraﬃn excess, followed by ethanol
washes. Proteins were degraded by digestion buﬀer using added protease
solution at 50/80C. Samples were bound to a spin-ﬁlter by addition of
isolation buﬀer and ethanol. DNA was degraded by DNAse treatment. The
ﬁlter was washed several times and total RNA was eluted in 60 µl elution
solution. Total RNA quantity and quality were checked by spectrophotome-
ter (Nanodrop ND-1000).
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MicroRNA microarray
From each sample 500 ng of total RNA was labeled with Hy3 ﬂuorescent
dye using the miRCURY LNA Array power labeling kit (Exiqon, Denmark).
In brief, total RNA was mixed with a spike-in mix containing 52 diﬀerent
synthetic unlabeled miRNAs and ﬂowingly treated with Calf Intestinal Al-
kaline Phosphatase (CIP) to catalyze the 5’ phosphate group’s removal in
order to prevent self-ligation for 30 min at 37C. The CIP treated RNA was
labeled with Hy3 by addition of labeling buﬀer, ﬂuorescent Hy3 label, DMSO
and labeling enzyme, and incubated at 16C. All samples were labeled the
same day with the same master mix, in order to minimize technical variation.
The Hy3-labelled samples were hybridized to miRCURY LNA arrays
(v11.0) (Exiqon, Denmark), which contains capture probes targeting all
human miRNAs registered in the miRBASE version 15.0 at the Sanger
Institute as well as a selection of other small RNAs. The hybridization was
performed according to manufacturer speciﬁcations using a Tecan HS4800
hybridization station (Tecan, Austria). Slides are loaded into the Tecan
Hybridization station and primed with 1 x hybridization buﬀer. 50 µl sample
is injected and the inlet is ﬂushed with 10µl 1x hybridization buﬀer. Sample
is hybridized to the slide at 56C for 16 hrs. at medium agitation. The slides
are washed several times at room temperature with wash buﬀers of varying
salt- and detergent concentration. Finally the slides are dried using pure
nitrogen. Since it was not possible to hybridize all arrays in one go, samples
were randomly spilt into 5 batches as to minimize day-to-day variation in
the hybridization process.
After hybridization the microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies, Inc., USA) at
5µm resolution and the resulting TIFF images segmented using the ImaGene
8.0 software on standard settings (BioDiscovery, Inc., USA).
Reverse transcription and Quantitative PCR (RT qPCR)
MicroRNAs were quantiﬁed using the miRCURY LNA™ Universal RT mi-
croRNA PCR kit (Exiqon, Hørsholm, Denmark) according to manufacturer’s
protocol. Brieﬂy, reverse transcription (RT) was performed using 40 ng of
total RNA from each sample. For quality control of the cDNA synthesis,
RNA spike-in was added to each RT reaction, and later quantiﬁed using
Control primers included in the kit. The miRNAs let-7g, miR-16, miR-
24-2, miR-27a, miR-27b, miR-29a, miR-29b, miR-29c, miR-30e, miR-122,
miR-199a, miR-320b, miR-1248 and miR-1908 (nomenclature according
to miRBase 18) were quantiﬁed using LNATM PCR primer sets, and the
reference RNAs SNORD44 and SNORD48 were used for normalization of
input RNA. RT-qPCR was performed using the LightCycler 480 instrument
(Roche diagnostics, Basel, Switzerland) and the conditions recommended by
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Exiqon for 42 lymphoma samples. The PCR cycle crossing point (Cp) was
determined for each well and Cp estimates from two technical replicates for
each probe-set were combined to produce one signal by taking the mean of
reliable wells.
Analysis of miRNA expression array
All microarray data processing steps were performed using the R environ-
ment [143]. The Genepix median intensities were read into R using LIMMA
package [172]. Further, the normexp method of background correction
(with oﬀset=10) was applied [152] to correct for spatial biases. This step
was followed by within-array normalization using global loess. To reduce
variance between arrays, we applied cubic spline normalization [152, 173].
For the diﬀerential expression analysis between eDLBCL and eMALT, only
foreground intensities were used. Empirical Bayes moderated t-test statistic
were obtained using LIMMA package [172, 170]. P-values were adjusted
using the Benjamini-Hoeschberg correction method [7].
MicroRNA regulatory network
Predicted and validated set of targets of the signiﬁcantly diﬀerentially ex-
pressed miRNA were obtained from MiRwalk [44]. Transcription factor (TF)
- miRNA interactions were obtained from transmiR database [186].
Results
Cohort summary
Of the 19 patients with eMALT, 10 were men. The median age was 70
years (range 26-90 years). Thirteen patients (79%) presented with Stage I
lymphoma and six patients (21%) had Stage IV lymphoma. Information
of treatment methods was available in 12 patients. Of these, 9 (75%) pa-
tients were treated with radiation therapy, and 3 (25%) received systemic
chemotherapy. All patients achieved complete remission and none had a
relapse. The 5-year overall survival for the entire population was 79%.
The 25 patients with ocular DLBCL had male predominance (15/25,
60%), and the median age was 78 years (range 35-97 years). Thirteen
patients (52%) presented with Stage I lymphoma. Of these 12 (92%) were
diagnosed with primary Lymphoma. Three patients (12%) had Stage II, one
patient (4%) had Stage III and 8 patients (32%) presented with Stage IV
lymphoma. Nine of the DLBCL patients were classiﬁed as GCB and sixteen
as non-GCB type. Systemic chemotherapy was applied in 16 of the patients
(68%), seven patients (28%) were treated with radiation therapy, and one
patient (4%) had surgery. Sixteen of the 25 patients experienced a relapse.
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Table 7.1. Diﬀerentially expressed miRNAs for eDLBCLs rel-
ative to eMALT, log-fold-changes (LFC) and their associated
p-values (adjusted p-value < 0.01)
miRNA LFC P-value miRNA LFC P-value
Down-regulated miRNAs
miR-24-2 -2.45 6.98E-44 miR-222 -0.98 3.26E-19
miR-29a -2.12 1.97E-31 miR-27a -0.97 2.57E-17
miR-29b -2.10 5.53E-28 miR-342-3p -0.96 5.72E-15
miR-24-1 -2.08 7.49E-44 miR-548g -0.96 3.35E-05
miR-29c -1.93 1.96E-26 miR-320c -0.95 4.85E-20
miR-26a -1.62 7.42E-27 miR-1297 -0.93 4.93E-24
miR-26b -1.62 1.65E-29 miR-1200 -0.90 1.02E-09
let-7g -1.56 6.50E-34 miR-137 -0.88 2.27E-05
miR-140-3p -1.29 1.04E-29 miR-708 -0.87 4.72E-30
miR-142-3p -1.27 7.48E-17 miR-23b -0.87 1.95E-10
miR-451 -1.18 2.51E-08 miR-27b -0.87 2.52E-13
miR-27a -1.15 7.42E-27 let-7a -0.85 2.81E-13
miR-142-5p -1.12 5.01E-13 miR-145 -0.84 6.34E-11
miR-16 -1.10 2.41E-18 miR-24 -0.83 1.86E-11
miR-125b -1.09 3.07E-10 miR-30c -0.82 5.82E-18
miR-30e -1.07 2.64E-13 miR-1248 -0.81 4.43E-16
miR-101 -1.06 2.30E-16 miR-30b -0.80 8.89E-12
miR-199a-5p -1.01 5.51E-09 miR-221 -0.79 3.88E-15
miR-199a-3p -1.01 4.66E-08 let-7f -0.74 3.22E-11
miR-645 -1.00 7.41E-18 miR-98 -0.73 2.65E-10
miR-143 -0.99 1.31E-09
Up-regulated miRNAs
miR-663b 0.71 5.44E-06
miR-30b 0.85 6.66E-09
The 5-year overall survival the entire group was 13%.
Comparison of miRNA expression proﬁles in MALT and DLBCL
Out of the 1900 RNA species analyzed on the array, 892 human mature-
miRNAs (miRBase release 14.0) were investigated for 43 lymphoma samples.
No clear correlation was observed between the known immuno-stratiﬁcation
of the samples, according to the HANS classiﬁcation, and the miRNA expres-
sion proﬁles, as seen in Figure 7.1. Diﬀerential expression analysis identiﬁed
43 signiﬁcantly diﬀerentially expressed miRNAs in eDLBCL vs. eMALT,
2 up-regulated and 41 down regulated in DLBCL relative to MALT, see
Table 7.1.
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Figure 7.1. Two-dimensional hierarchical clustering of ocular
MALT-type and diﬀuse large B-cell lymphomas shown for an
un-biased selection of miRNA genes. The dendrogram rep-
resents a clustering of 892 miRNAs using ward linkage hier-
archical clustering and the Euclidean distance between mean
centered and variance scaled miRNA proﬁles, i.e. miRNA Z-
scores.
Supervised hierarchical clustering of the signiﬁcantly diﬀerential
expressed miRNAs
To further characterize the miRNAs that were diﬀerentially expressed be-
tween eMALT and eDLBCLs we performed a supervised clustering. Using
this approach only two outliers were observed (Figure 7.2). Although the
analysis of histology did not reveal any characteristic features of these two
tumors, sample 186 of eMALT type showed a higher level of the proliferation
marker KI67. The other outlier (sample 228) was a DLBCL that clustered
with the MALT type lymphomas. Interestingly this sample had a relatively
low proliferation marker of 30%.
RT-qPCR based validation was performed for 15 miRNAs, including
12 miRNAs that were found to be diﬀerentially expressed using microar-
rays (let-7g, miR-16, miR-29a, miR-29b, miR-29c, miR-199a-5p, miR-222,
miR-24, miR-27a, miR-27b, miR-30e, miR-1248); miR-129-5p and miR-1908
which were not found to be diﬀerentially expressed; miR-320b, that diﬀers in
mature RNA sequence only slightly from miR-320c which was diﬀerentially
expressed. The Pearson correlation coeﬃcients (PCC) between microarray
and qPCR measurements ranged from –0.66 to -0.95, due to inverse re-
lationship between Cp values and miRNA concentrations for 11 of the 13
tested miRNAs. All 13 miRNA correlation coeﬃcients in this range were
found to be signiﬁcant (p < 0.01), while miR-1908 and the negative control
(miR-129-5p) were not found to be signiﬁcant (CC0̃). Of the 13, 9 exhibited
PCC < -0.90 (p < 1e-15) and 2 exhibited -0.86 < PCC < -0.66 (p < 1e-5).
Correlations analysis and PCC values can be seen in Supplementary Fig-
ure 7.2. Of the 12 signiﬁcantly diﬀerentially expressed miRNAs found using
microarrays, qPCR conﬁrmed diﬀerential expression of 10 (let-7g, miR-16,
7.2. MANUSCRIPT 81
215
218
229
231
200
409
403
408
406
407
207
210
230
206
216
226
203
221
232
186
209
222
400
401
223
217
227
187
228
196
194
143
188
127
135
134
126
137
146
133
125
144
195
145
189
hsa−miR−29c
hsa−miR−29a
hsa−miR−29b
hsa−miR−142−3p
hsa−miR−142−5p
hsa−let−7g
hsa−miR−16
hsa−miR−140−3p
hsa−miR−26b
hsa−miR−26a
hsa−miR−101
hsa−miR−30e
hsa−miR−27a
hsa−miR−27b
hsa−miR−451
hsa−miR−125b
hsa−miR−24
hsa−miR−23b
hsa−miR−199a−5p
hsa−miR−199a−3p
hsa−miR−145
hsa−miR−143
hsa−miR−342−3p
hsa−miR−222
hsa−miR−221
hsa−miR−1248
hsa−miR−30b
hsa−let−7a
hsa−miR−98
hsa−miR−30c
hsa−miR−1297
hsa−let−7f
hsa−miR−30b*
hsa−miR−663b
hsa−miR−137
hsa−miR−548g
hsa−miR−708
hsa−miR−320c
hsa−miR−24−2*
hsa−miR−24−1*
hsa−miR−1200
hsa−miR−27a*
hsa−miR−645
type
DLBCL−GCB
DLBCL−nonGCB
MALT
−4
−2
0
2
4
Figure 7.2. Two-dimensional hierarchical clustering of ocu-
lar MALT-type and diﬀuse large B-cell lymphomas for the 43
signiﬁcantly diﬀerentially expressed miRNAs between MALT
and DLBCL. The 41 miRNAs down-regulated in DLBCL show
a less variable pattern across patient samples relative to the 2
miRNAs up-regulated in DLBCL
miR-29a, miR-29b, miR-29c, miR-199a-5p, miR-222, miR-27a, miR-30e and
miR-1248) as shown in Figure 7.2. Points outside the grey area pass the
signiﬁcance thresholds for logFC (absolute log2FC0.7 and p-value0.05).
The overall correlation in terms of fold-changes and the p-values were -0.636
and 0.75, respectively. In summary, an excellent correlation between array
and qPCR results was observed.
Suppression of MYC regulated miRNAs in diﬀuse large B-cell
lymphoma
MYC, a transcription factor (TF) and a lymphoma-associated oncoprotein,
controls various steps of normal B-cell development. Dysregulation or a
gain-of-function of MYC in various human malignancies, particularly in
lymphomagenesis, suggests its crucial role in regulation of protein-coding
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and non-coding genes in tumorigenesis. TransmiR [186], a database of
TF-miRNA regulation, reports that MYC regulates 38 miRNAs (MYC-miR
interactions), of which 24 miRNAs are known to negatively regulated, 10
miRNAs to be positively regulated and 4 are under an undetermined regu-
latory inﬂuence of MYC. the down-regulated miRNAs, let-7g, let-7f, let-7a,
miR-23b, miR-26a, miR-29a and miR-29c have been reported to be under
direct negative regulation of MYC [26, 27, 162, 166], as seen in Figure 7.4.
Further, MYC has been observed to bind the promoter upstream of tumor
suppressor let-7 family pri-miRNAs [26]. Target predictions obtained for let-
7 family miRNAs and miR-26a include MYC and other cancer-related genes,
such as BCL2, BCL6, BRAF, EGFR, DICER1, KRAS, MAP2K4, MYCN,
NRAS, RUNX1, TNFAIP3, TNFRSF14 and TP53. This implies a negative
feedback loop between MYC and the MYC-repressed miRNAs. Such nega-
tive feedback loops result in the loss of post-transcriptional regulation of let-7
family and miR-26a targets, leading to up-regulation of oncogenes. Targets
of MYC-repressed miRNAs, together with MYC-induced oncogenes, may
contribute to tumorigenesis and transformation of eMALT to eDLBCL. Our
ﬁnding is in agreement with previous study [38] on transformation of gastric
MALT to gastric DLBCL, which also suggested a role for MYC dysegulation
in MALT-DLBCL transformation.
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Figure 7.3. Agreement of the diﬀerential expression and cor-
responding p-values measured by microarrays and RT-qPCR.
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the log2 fold-change and p-value thresholds (absolute log2 fold-
change 0.7 and p-value0.05
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Activation of NF-KB signaling via loss of miRNA-regulation
Target prediction for the diﬀerentially expressed miRNAs revealed a small
set of miRNAs regulating NFKB1. These miRNAs include, let-7g, miR-1275,
miR-199a-5, miR-26a, miR-27a and miR-342. All, except for miR-1275,
showed down-regulation in eDLBCL relative to eMALT samples. This hints
toward a loss of regulation of NFKB1 through its regulatory miRNAs.
We suggest that an aberrant activation of NFKB signaling through either
chromosomal aberrations, or due to a loss of miRNA-mediated regulation
may lead to an over-expression of NFKB1. Furthermore, NFKB1 also
transcriptionally regulates the expression of miR-29 family members and
miR-125b NFKB1. It has been previously shown that NFKB1 suppresses
transcription of miR-29a/b/c and miR-125b by binding to their upstream
promoters [185]. In agreement with this plausible mechanism, we observed
signiﬁcant down-regulation of these miRNAs in eDLBCL relative to eMALT
(log2 fold-changes: miR-29a/b/c < -1.9 and -1.08 for miR-125b), see Fig-
ure 7.4.
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Figure 7.4. TF-miRNA interactions for the most signiﬁcantly
diﬀerentially expressed miRNAs in eDLBCL as curated by
transmiR database
Discussion
Ocular adnexal lymphoma is a group of malignancies with heterogeneous
clinical, molecular and pathological characteristics. MALT in ocular regions
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is one of the most frequent types of lymphomas in eye that despite being
indolent initially, often transform into the malignant high-grade diﬀuse large
B-cell lymphoma of eye. In the present study we investigated the role of
miRNAs in disease transformation from eMALT to eDLBCL by miRNA
expression proﬁling of FFPE specimens from patients suﬀering from these
diseases.
We observed 43 diﬀerentially expressed miRNAs between eMALT and
eDLBCL samples, a majority of which (41) were found at lower levels in
DLBCL than in MALT. A selected set of these miRNAs was validated
by RT-qPCR on all patient material. Of the thirteen miRNAs for which
qPCR validations were performed, 9 showed a signiﬁcant correlation to their
expression proﬁles (PCC < -0.90, p < 1e-15) and 2 exhibited a PCC ranging
from -0.86 to -0.66 (p < 1e-5). miR-29 family miRNAs, miR-222, let-7g and
miR-199-5p showed highest and most signiﬁcant correlations between their
gene expression signatures and Cp values. The diﬀerential expression of the
selected miRNAs measured by microarrays was in agreement with the one
measured using qPCR (correlation of log2 fold-change, -0.636 and of the
p-values, 0.75).
The miRNAs signiﬁcantly down-regulated in DLBCL included miR-29a,
miR-29a and miR-24 family of miRNAs; and miR-221/222, miR-23a and
miR-29 cluster. miR-29a/c have been previously reported to be under a
negative transcriptional regulation by MYC and NFKB1. We also observed
a signiﬁcant down-regulation of other known MYC suppressed miRNAs such
as miR-26a, let-7g, and miR-221. let-7g is also repressed by LIN28B, a
protein that is trans-activated by MYC. However, it has been shown that the
presence of Lin28B is a necessary and suﬃcient condition for MYC-mediated
repression of let-7g and does not change the expression of pri-let-7 [26]. In
summary, at least 7 of 29 down-regulated miRNAs are known to be under
transcriptional repression by MYC. Interestingly, known upstream regula-
tors of MYC, miR-142-3p/5p, were one of the most down-regulated miRNAs
(more than two-fold down-regulation). Thus, a loss-of-function of miR-142
may have resulted in MYC over expression, and thereby a repression of
several tumor suppressive miRNAs.
Aberrant activation of NF-B signaling pathway has repeatedly been
linked to the aggressive forms of diﬀuse large B-cell lymphoma [110]. Such
aberrant activation in MALT and DLBCL may result from recurrent chro-
mosomal anomalies, such API2/MALT1 and IGH/MALT1 translocations,
as previously reported in 30% to 50% of extranodal MALT lymphomas [81].
The oncogenic fusion protein API2/MALT1 or an IGH-mediated activation
of MALT1 due to IGH/MALT1, results in to hyperactivation of NF-Kb
signaling pathway. However, genetic regulatory mechanisms upstream of
NFKB1, a key gene for NFKB signaling event, may also lead to an aberrant
expression and activation of NF-KB pathway. We observed that four out of
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ﬁve regulatory miRNA of NFKB1 showed a signiﬁcant down regulation in
eDLBCL, suggesting a loss-of-regulation event through upstream miRNA-
regulators of NFKB1. Therefore, we hypothesize that NFKB1 expression
might exhibit an increase after its escape from miRNA-mediated regulation.
Interestingly, we also observe that NFKB1 regulated miRNAs, miR-29a/b/c
were also signiﬁcantly down-regulated in DLBCL. NFKB1 has been reported
as a transcriptional regulatory of miR-29a/b/c and it has negative regulatory
eﬀect. In addition, the largest down-regulation events were observed for the
miR-29 family, which is also transcriptionally suppressed by YY1 (ying-yang
1), a zinc ﬁnger protein, over-expression of which has been linked with a
shorter survival in DLBCL and follicular lymphomas [185, 161]. This in-
triguing ﬁnding deserves experimental validation of mRNA or protein levels
of MYC, NFKB1 and YY1 in freshly frozen samples as these measurements
are, unfortunately, not possible with FFPE samples.
Among the down-regulated miRNAs, miR-16, miR-221, miR-26b, miR-
24, miR-23b, miR-27b, and miR-30e have previously been linked with B-cell
lymphomas [26, 197] and other lymphoproliferative disorders [20]. Further,
the down-regulated miRNAs were enriched for tumor suppressive miRNAs,
let-7a/f/g, miR-16, miR-451, miR-26a/b, miR-145, miR-143, miR-125b,
miR-101, miR-29a/c and miR-98. This ﬁnding suggests a systematic repres-
sion of tumor suppressor miRNAs during the transformation of MALT to
DLBCL.
In summary, a large scale repression of tumor suppressive miRNAs ob-
served during the transformation of eMALT to eDLBCL provides hints to-
ward their potential in diagnostics and therapeutics.
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Figure 7.5. Correlation plots showing good correlation be-
tween microarray and RT-qPCR determined miRNA levels
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Chapter 8
Summary & future perspectives
This thesis presents projects that elucidate the role of miRNAs in drug
resistance in ER-positive breast cancers and in the disease transformation
from ocular MALT to ocular DLBCL. The projects herein, describe analyses
of data obtained using various gene expression proﬁling technologies. The
statistical methods are applied such that to reduce the technical variation as
much as possible and to highlight the biological diﬀerences between sample
types. Further, the projects describe herein, integrate various lines of evi-
dence coming from gene regulation by miRNAs, TF-miRNA, TF-DNA and
protein-protein interactions.
Patients with ER-positive breast cancer are often given an adjuvant
treatment with antiestrogen drugs such as Tamoxifen.Tamoxifen is highly
eﬀective in reducing the risk of recurrence after primary treatment, as well
as in reducing risk of developing the disease for the patients with high-risk
of developing breast cancer. Chapter 6 presents an integrative analysis of
miRNA-target relationships for tamoxifen resistance in ER-positive breast
cancer. Inverse correlations between miRNA and their targets were exploited
to derive functional miRNA-target relationships. The miRNA-regulated
genes were investigated for the pathways they might inﬂuence. From the
functional enrichment analysis of miRNA-regulated diﬀerentially expressed
genes, we determined several receptor signaling events, aurora B kinase
signaling, FOXM1 signaling, etc. were aﬀected by miRNA-mediated regu-
lation. Further, with the integration of existing knowledge on TF-mediated
regulation of miRNAs and protein coding genes, a linear pathway involving
FOXM1, miR-135a and EPHA4/7 was identiﬁed. In addition, this study
also highlights several detailed lines of events possibly contributing to the
tamoxifen resistance.
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Ocular adnexal lymphomas are the most common type of malignancies
in the eye, covering intraocular and orbital (eyelid, lacrimal glands, conjunc-
tiva, etc) regions. Mucosa associated lymphoid tissue lymphoma (MALT)
and diﬀuse large B-cell lymphoma (DLBCL) is the most common extranodal
malignancies in the eye. When untreated, MALT, a relatively indolent
disease often transforms into the malignant DLBCL. Chapter 7 presents
a project in which global alterations in the miRNA expression during the
transformation of ocular MALT to ocular DLBCL were studied. Majority of
these alterations referred to the repressed levels of tumor suppressor miRNAs
in DLBCL. Dysregulated miR-29a/c, let-7a, let-7g, miR-23b, miR-26a and
miR-221 are known to be under MYC-mediated transcriptional repression.
miR-29 family members, down-regulated in DLBCL, are also known to be
the transcriptional targets of NFKB1 and YY1. Diﬀerential expression of 10
out of 12 diﬀerentially expressed miRNAs was validated and conﬁrmed by
qPCR. Several other repressed miRNAs had a tumor suppressive eﬀect. The
study indicates a potential use of the dysregulated miRNAs in diagnostics
or in therapeutics.
Experimental design is the most crucial step if the statistically and biolog-
ically valid conclusions are to be drawn from the data. The project described
in Chapter 6 began with a miRNA expression proﬁling using small RNA-seq
technologies. Various read alignment strategies were attempted to highlight
the biological variation between cell lines as much as possible, diﬀerential
expression analysis was carried out. However, in the absence of replicate
measurements on the same cell lines, tests for diﬀerential expression did
not yield statistical power and were insuﬃcient to draw a sound conclusion.
Therefore, a miRNA qPCR proﬁling with three replicate measurements were
performed. In order to understand the impact of miRNA expression, we in-
tegrated microarray data obtained on the same RNA. The inverse correlation
analysis, as outlined in the manuscript I, should ideally be performed with
as many measurements available for miRNA and gene expression measure-
ments. However, since the gene expression proﬁling experiment was planned
prior to miRNA qPCR, we did not have matching number of samples for
each cell line. Therefore, the mean expressions of replicate measurements for
each cell line were obtained to perform an inverse correlation analysis. This
may have dampened positive correlations between miRNA and mRNA pairs,
and hence the analysis may have missed functional miRNA-target pairs. For
such type of analysis of inferring miRNA-target relationships, we would like
to plan the experiments such that we have the matching number of replicates
for each sample type for miRNA and mRNA datasets.
For the project described in Chapter 7, the primary goal was to identify
miRNAs with altered expression between ocular MALT and ocular DLBCL.
Since DLBCL is a heterogeneous disease, the secondary goal was to obtain
miRNA signatures that may identify molecular sub-groups of DLBCL. We
applied an adaptive gene shaving approach to DLBCL dataset consisting of
91
25 patient samples (described in Chapter 5). We were able to successfully
identify sub-groups of DLBCL samples with distinct miRNA expression
signatures. However, the correlation of the sample sub-groups to clinical
characteristics did not yield statistically signiﬁcant associations. We account
the smaller population ( N=25) and shorter patient survivals (median age
 75 years) for the lack of statistical signiﬁcance. Although not the goal of
the study, it would be very interesting to study gene expression changes and
chromosomal aberrations together with changes in miRNA expression during
the transformation from MALT to DLBCL. Unfortunately, the available
patient samples are FFPE (formalin ﬁxed paraﬃn embedded), and therefore
it is rather diﬃcult to obtain good quality mRNA from them.
In summary, this thesis presents studies that point toward various crucial
roles of miRNAs in anti-estrogen resistance and in disease transformation.
The results obtained by following the systems biology approach provide hints
toward several biological events that may carry therapeutic and diagnostic
potential.
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